[
  {
    "product_code": "BI 3822971",
    "product_name": "Not disclosed",
    "modality_name": "T-cell Engager",
    "process_template_name": null,
    "product_type": "NBE (ntm)",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Bispecific antibody binding LY6K-HLA-A*02:01 on tumor cells and CD3ε on T cells to induce tumor-specific cytotoxicity; Fc engineered for half-life extension and reduced effector function.",
    "short_description": "Bispecific TcE for NSCLC inducing tumor-specific T‑cell cytotoxicity via LY6K‑HLA/CD3 engagement.",
    "description": "BI 3822971 is a bispecific T‑cell engager that binds the LY6K‑HLA‑A*02:01 complex on tumor cells and CD3ε on T cells to drive tumor‑specific cytotoxicity. Its Fc is engineered for half‑life extension and reduced effector function.\n\nThe scientific rationale is selective targeting of the LY6K‑HLA complex to enable tumor‑specific T‑cell activation with strong in vitro cytotoxicity and minimal off‑target effects. Drug class: bispecific antibody / T‑cell engager.",
    "dosage_form": "Injectable (IV; SC possible later)",
    "route_of_administration": "IV; SC (possible later)",
    "base_technology": "T‑cell engager (CD3×pMHC)",
    "biel_category": null,
    "current_phase": "Preclinical",
    "project_status": null,
    "lead_indication": "NSCLC",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": {
      "high": [
        "HLA restriction",
        "CRS/ICANS",
        "Off-tumor expression"
      ]
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Comprehensive Product Profile: BI 3822971**\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3822971\n- **Product Name:** Not disclosed\n- **Label:** NBE (ntm)\n- **Modality Category:** Engineered Biologics\n- **Modality Name:** T-cell Engager\n- **Therapeutic Area:** Oncology (NSCLC, HNSCC, SCLC, EC)\n- **Strategic Classification:** Bispecific TcE targeting LY6K-HLA/CD3\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Bispecific antibody binding LY6K-HLA-A*02:01 on tumor cells and CD3ε on T cells to induce tumor-specific cytotoxicity; Fc engineered for half-life extension and reduced effector function.\n- **Scientific Rationale:** Selective targeting of LY6K-HLA complex enables tumor-specific T-cell activation; strong in vitro cytotoxicity with minimal off-target effects.\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (IV; SC possible later)\n- **Manufacturing Strategy:** Internal; affinity constants: KD 0.38 nM (LY6K/HLA), 150 nM (human CD3)\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** NSCLC\n- **Development Phase:** Preclinical\n- **Regulatory Designations:** None\n\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** 2034\n- **Operational Status:** Preclinical safety and tissue distribution studies ongoing\n\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| HNSCC | Oncology | Preclinical | TBD | Shared platform |\n| SCLC / EC | Oncology | Preclinical | TBD | Exploratory |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Internal\n- **Volume:** TBD\n\n---\n\n### 8. Risks & Mitigation\n- **Risks:** HLA restriction; CRS/ICANS; off-tumor expression\n    - *Mitigation:* Fc engineering; exhaustive selectivity screens\n---\n\n### 9. Clinical Trial Information\n- **Status:** Preclinical; FiH not yet initiated\n\n---"
  },
  {
    "product_code": "BI 3968621",
    "product_name": "Not disclosed",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "PROTAC targeting HPK1 for proteasomal degradation via CRBN E3 ligase recruitment; enhances T/B/DC activation to boost anti-tumor immunity.",
    "short_description": "Oral PROTAC degrading HPK1 to boost immune activation for RCC; preclinical development.",
    "description": "BI 3968621 is an oral PROTAC that recruits the CRBN E3 ligase to induce proteasomal degradation of HPK1, a negative regulator of immune activation. By degrading HPK1, it aims to enhance T, B, and dendritic cell activation to improve anti‑tumor immunity.\n\nThe rationale is that HPK1 suppression may synergize with checkpoint inhibitors and augment immune responses across solid tumors. Drug class: PROTAC (heterobifunctional degrader).",
    "dosage_form": "Oral tablet",
    "route_of_administration": "Oral",
    "base_technology": "Targeted protein degrader (CRBN‑recruiting PROTAC)",
    "biel_category": null,
    "current_phase": "Preclinical",
    "project_status": null,
    "lead_indication": "RCC",
    "expected_launch_year": 2035,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": {
      "high": [
        "Lung toxicity at high doses",
        "Immune dysregulation"
      ]
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Comprehensive Product Profile: BI 3968621**\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3968621\n- **Product Name:** Not disclosed\n- **Label:** NCE (solid)\n- **Modality Category:** Engineered Biologics\n- **Modality Name:** PROTAC\n- **Therapeutic Area:** Oncology (RCC, NSCLC, HNSCC)\n- **Strategic Classification:** Oral HPK1 degrader\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** PROTAC targeting HPK1 for proteasomal degradation via CRBN E3 ligase recruitment; enhances T/B/DC activation to boost anti-tumor immunity.\n- **Scientific Rationale:** HPK1 is a negative regulator of immune activation; degradation may synergize with checkpoint inhibitors.\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Oral tablet\n- **Manufacturing Strategy:** Internal; estimated human dose 150 mg QD\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** RCC\n- **Development Phase:** Preclinical\n- **Regulatory Designations:** None\n\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** 2035\n- **Operational Status:** Preclinical tox: NOAEL 100 mg/kg/day; lung toxicity at 300 mg/kg/day\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| RCC | Oncology | Preclinical | 2035 | Lead |\n| NSCLC | Oncology | Preclinical | TBD | Expansion |\n| HNSCC | Oncology | Preclinical | TBD | Expansion |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Internal\n- **Volume:** TBD\n\n---\n\n### 8. Risks & Mitigation\n- **Risks:** Lung toxicity at high doses; immune dysregulation\n    - *Mitigation:* Conservative SAD/MAD; translational biomarkers\n\n---\n\n### 9. Clinical Trial Information\n- **Status:** No trials yet; FiH not initiated\n\n---"
  },
  {
    "product_code": "BI 655130",
    "product_name": "Spesolimab",
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Immunology; Neutrophilic Dermatoses",
    "mechanism_of_action": "Humanized IgG1 monoclonal antibody antagonizing IL-36 receptor (IL-36R), blocking IL-36α, IL-36β, and IL-36γ signaling.",
    "short_description": "Anti-IL-36R monoclonal antibody approved for GPP flares, investigational for pyoderma gangrenosum; IV for flares, SC for prevention.",
    "description": "Spesolimab is a humanized IgG1 monoclonal antibody that antagonizes the IL‑36 receptor (IL‑36R), blocking IL‑36α, IL‑36β, and IL‑36γ signaling. By interrupting the IL‑36 pathway driving neutrophilic inflammation, it aims to enable rapid wound healing and reduce disease burden in PG.\n\nDrug class: monoclonal antibody. The value proposition builds on the GPP precedent, positioning Spesolimab as a first targeted therapy for PG with an IV regimen for acute flares and an SC regimen for prevention.",
    "dosage_form": "IV for acute flare; SC for long-term prevention",
    "route_of_administration": "Injectable",
    "base_technology": null,
    "biel_category": null,
    "current_phase": "Marketed (GPP flares)",
    "project_status": null,
    "lead_indication": "Pyoderma Gangrenosum (PG)",
    "expected_launch_year": 2027,
    "patient_population": "Adults with active PG lesions.",
    "primary_packaging": "Vial; Prefilled syringe",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": {
      "Systemic Sclerosis (SSc)": [
        "Fast Track"
      ]
    },
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": {
      "medium": [
        "Limited biomarker data for IL-36 in PG",
        "Recruitment challenges in rare disease"
      ]
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": {
      "phase_3": {
        "trial_name": null,
        "indication": "Pyoderma Gangrenosum (PG)",
        "status": "Ongoing"
      }
    },
    "raw_content": "### **Comprehensive Product Profile: Spesolimab (anti-IL36R)**\n\nThis profile integrates clinical, operational, and strategic data from all available documents to provide a complete view of the asset.\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** Not explicitly stated\n- **Product Name:** Spesolimab\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area:** Immunology / Neutrophilic Dermatoses\n- **Strategic Classification:** NBE_NTM (New Biological Entity – New Therapeutic Modality)\n\n*(Source: Internal immunology pipeline and dermatology strategy documents)*\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Humanized IgG1 monoclonal antibody antagonizing IL-36 receptor (IL-36R), blocking IL-36α, IL-36β, and IL-36γ signaling.\n- **Scientific Rationale:** IL-36 pathway drives neutrophilic inflammation in PG and other dermatologic conditions. Spesolimab interrupts this cascade, enabling rapid wound healing and reducing disease burden.\n- **Drug Class:** Monoclonal antibody\n- **Value Proposition:** First targeted therapy for PG; leverages GPP precedent for efficacy and safety.\n\n*(Source: Clinical pharmacology and dermatology portfolio reports)*\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** IV for acute flare; SC for long-term prevention\n- **Primary Packaging:** Vial or prefilled syringe (based on GPP precedent)\n- **Route of Administration:** Injectable\n- **Manufacturing Strategy:** Internal; same network as GPP indication\n\n*(Source: Manufacturing readiness and supply chain documents)*\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** Pyoderma Gangrenosum (PG)\n- **Development Phase:** Phase III\n- **Regulatory Designations:** None specific to PG; Fast Track for Systemic Sclerosis\n- **Partnerships:** Internal development\n\n*(Source: Clinical development tracker and regulatory planning)*\n\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** 2027\n- **Submission Scenarios:** 2H 2026 (Week 26 endpoint) or 1H 2027 (Week 52 endpoint)\n- **Operational Status:** Phase III ongoing; RWE strategy active (SEQSTER registry, COA, natural history)\n\n*(Source: Launch planning and RWE strategy documents)*\n\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| Generalized Pustular Psoriasis (GPP) | Immunology | Launched | Approved in 53 countries | IV for flares; SC for prevention |\n| Hidradenitis Suppurativa (HS) | Immunology | Discontinued | — | Development halted post-Phase IIb |\n| Systemic Sclerosis (SSc) | Immunology | Phase II | 2026 | Fast Track designation |\n| Netherton Syndrome (NS) | Immunology | Preclinical/Early | TBD | Exploratory |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Internal; leveraging GPP infrastructure\n- **Volume Category:** Moderate; PG is rare but requires specialized care in academic centers\n- **Engagement:** Academic center partnerships and PAG involvement critical for recruitment and adoption\n---\n\n### 8. Risks & Mitigation\n- **Scientific Risk:** Limited biomarker data for IL-36 in PG\n    - *Mitigation:* RWE and biomarker studies embedded in development plan\n- **Operational Risk:** Recruitment challenges in rare disease\n    - *Mitigation:* Global site network and patient advocacy engagement\n\n---\n\n### 9. Clinical Trial Information\n- **Population:** Adults with active PG lesions\n- **Design:** Phase III with Week 26 and Week 52 endpoints; tokenization for data linkage\n- **RWE:** SEQSTER registry, COA, natural history studies to support access and evidence generation\n---"
  },
  {
    "product_code": "BI 3814916",
    "product_name": "Not yet assigned",
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Hepatologie (ACLF)",
    "mechanism_of_action": "Anti-TLR4 monoclonal antibody.",
    "short_description": "Anti-TLR4 monoclonal antibody for Acute-on-Chronic Liver Failure (ACLF).",
    "description": "BI 3814916 is a monoclonal antibody that inhibits TLR4 signaling to reduce hepatic and systemic inflammation associated with MASH.\n\nRationale: TLR4 ligands drive inflammation and fibrosis in MASH; BI 3814916 blocks IL‑6 release and TLR4 signaling in preclinical models. Drug class: monoclonal antibody (injectable).",
    "dosage_form": "Lösung zur Injektion/Infusion, 150 mg/mL (Vial)",
    "route_of_administration": "parenteral (i.v. oder s.c.)",
    "base_technology": null,
    "biel_category": null,
    "primary_packaging": null,
    "current_phase": "Phase I",
    "project_status": null,
    "lead_indication": "MASH",
    "submission_status": null,
    "launch_geography": null,
    "expected_launch_year": 2034,
    "patient_population": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": {
      "high": [
        "Infection risk",
        "Developmental toxicity",
        "IRR/hypersensitivity"
      ]
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Comprehensive Product Profile: BI 3814916**\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3814916\n- **Product Name:** Not yet assigned\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area:** CRM – MASH\n- **Strategic Classification:** Injectable mAb\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Monoclonal antibody inhibiting TLR4 to reduce hepatic/systemic inflammation in MASH.\n- **Scientific Rationale:** TLR4 ligands drive inflammation and fibrosis in MASH; BI 3814916 blocks IL-6 release and TLR4 signaling in preclinical models.\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (likely SC monthly)\n- **Manufacturing Strategy:** Internal biopharma facility; PDE set at 10 µg/day for occupational safety\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** MASH\n- **Development Phase:** Preclinical\n- **Regulatory Designations:** None\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** 2034\n- **Operational Status:** Limited nonclinical data; no clinical trials yet\n\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| MASH | CRM | Preclinical | 2034 | Lead |\n| Other TLR4-driven diseases | CRM/Immunology | Preclinical | TBD | Exploratory |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Early-stage; internal\n- **Volume:** TBD\n---\n\n### 8. Risks & Mitigation\n- **Risks:** Infection risk; developmental toxicity; IRR/hypersensitivity\n    - *Mitigation:* Staged tox; infection screening; conservative PDE\n\n---\n\n### 9. Clinical Trial Information\n- **Status:** Preclinical; no trials initiated\n---"
  },
  {
    "product_code": "BI 3819026",
    "product_name": "Anti-LAYN antibody",
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Humanized IgG1 anti-LAYN antibody targeting LAYN isoforms 1 and 2 to deplete tumor-resident Tregs and enhance anti-tumor immunity, with demonstrated CD16a binding. Afucosylation is not definitively documented.",
    "short_description": "IgG1 antibody targeting LAYN to deplete tumor Tregs in solid tumors, with demonstrated CD16a binding for enhanced ADCC.",
    "description": "BI 3819026 is a humanized, afucosylated IgG1 monoclonal antibody targeting LAYN isoforms 1 and 2 to deplete tumor‑resident regulatory T cells (Tregs) and enhance anti‑tumor immunity.\n\nRationale: Tregs suppress immune responses and limit checkpoint inhibitor efficacy; LAYN is enriched in tumor‑infiltrating Tregs, enabling selective immune modulation. Drug class: monoclonal antibody with enhanced ADCC due to afucosylation.",
    "dosage_form": "Konzentrat zur Herstellung einer Infusionslösung, 150 mg/mL (2 mL-Vial)",
    "route_of_administration": "intravenöse Infusion",
    "base_technology": "Afucosylated IgG1 (enhanced ADCC)",
    "biel_category": "3A",
    "primary_packaging": null,
    "current_phase": "Phase I (FIH)",
    "project_status": null,
    "lead_indication": "Solid Tumors",
    "submission_status": null,
    "launch_geography": null,
    "expected_launch_year": 2035,
    "patient_population": "Solid tumors with high Treg infiltration.",
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": {
      "medium": [
        "Early-stage formulation and analytics"
      ]
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": {
      "phase_1": {
        "trial_name": null,
        "indication": "Solid Tumors",
        "status": "Planned (FiH 2026)"
      }
    },
    "raw_content": "### **Comprehensive Product Profile: BI 3819026**\n\nThis profile integrates clinical, operational, and strategic data from all available documents to provide a complete view of the asset.\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3819026\n- **Product Name:** Anti-LAYN antibody\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area:** Oncology (Solid Tumors)\n- **Strategic Classification:** Afucosylated IgG1 antibody for Treg depletion\n\n*(Source: Internal oncology pipeline and CMC documentation)*\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Humanized afucosylated IgG1 targeting LAYN isoforms 1 and 2 to deplete tumor-resident Tregs and enhance anti-tumor immunity.\n- **Scientific Rationale:** Tregs suppress immune responses and limit checkpoint inhibitor efficacy. LAYN is enriched in tumor-infiltrating Tregs, making it a selective target for immune modulation.\n- **Drug Class:** Monoclonal antibody with enhanced ADCC potential due to afucosylation.\n\n*(Source: Preclinical immuno-oncology strategy reports)*\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (IV; SC under evaluation)\n- **Primary Packaging:** Not specified\n- **Route of Administration:** Parenteral\n- **Manufacturing Strategy:** Internal; analytical controls include CGE (non-reduced) and SEC with main peak ≥90%, HMW ≤5%.\n- **BIEL Category:** 3A\n- **Pregnancy Category:** 2\n\n*(Source: CMC development plans)*\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** Solid Tumors\n- **Development Phase:** Preclinical\n- **Regulatory Designations:** None\n- **FiH Start:** Planned for February 2026\n\n*(Source: Internal milestone tracker)*\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** 2026 (indicative; subject to clinical success)\n- **Operational Status:** Formulation and analytical validation ongoing; PDE set at 10 µg/day\n\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| Solid Tumors (IV) | Oncology | Preclinical | 2026 | Lead |\n| Solid Tumors (SC) | Oncology | Preclinical | TBD | Lifecycle option |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Internal\n- **Volume:** Low initial volumes\n- **Exposure Limits:** PDE 10 µg/day; PWE 70 µg/week\n\n---\n\n### 8. Risks & Mitigation\n- **CMC Risk:** Early-stage formulation and analytics\n    - *Mitigation:* Orthogonal methods; tight acceptance criteria\n\n---\n\n### 9. Clinical Trial Information\n- **Planned Population:** Solid tumors with high Treg infiltration\n- **Design:** SAD/MAD FiH planned for 2026\n\n---"
  },
  {
    "product_code": "BI 3821001",
    "product_name": "DcR3-Fc",
    "modality_name": "Recombinant Proteins",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Immunology; IBD",
    "mechanism_of_action": "Engineered decoy receptor 3 fused to silenced IgG1 Fc to neutralize TL1A and LIGHT, reducing inflammation and tissue remodeling in IBD.",
    "short_description": "Fc‑fusion decoy receptor neutralizing TL1A and LIGHT for inflammation control in ulcerative colitis.",
    "description": "BI 3821001 (DcR3‑Fc) is an engineered decoy receptor 3 fused to a silenced IgG1 Fc to neutralize TL1A and LIGHT, aiming to reduce inflammation and tissue remodeling in IBD.\n\nRationale: Dual TL1A/LIGHT blockade offers broader suppression of pro‑inflammatory pathways versus monospecific agents, supported by transcriptomic data confirming the mechanism of action. Drug class: recombinant protein (Fc‑fusion biologic).",
    "dosage_form": "Injectable (SC or IV)",
    "route_of_administration": "Injectable",
    "base_technology": "Engineered DcR3‑Fc (reduzierte FasL‑Affinität); dualer TL1A/LIGHT‑Trap",
    "biel_category": null,
    "primary_packaging": null,
    "current_phase": "Preclinical/SoD (Ende 2024)",
    "project_status": null,
    "lead_indication": "Ulcerative Colitis",
    "submission_status": null,
    "launch_geography": null,
    "expected_launch_year": 2035,
    "patient_population": "Moderate–severe ulcerative colitis.",
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": {
      "medium": [
        "Glycosylation/disulfide complexity"
      ]
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": {
      "phase_2b": {
        "trial_name": null,
        "indication": "Ulcerative Colitis",
        "status": "Preparation underway"
      }
    },
    "raw_content": "### **Comprehensive Product Profile: BI 3821001**\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3821001\n- **Product Name:** DcR3-Fc\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Recombinant Proteins\n- **Therapeutic Area:** Immunology / IBD\n- **Strategic Classification:** Dual TL1A/LIGHT inhibitor via Fc-fusion\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Engineered decoy receptor 3 fused to silenced IgG1 Fc to neutralize TL1A and LIGHT, reducing inflammation and tissue remodeling in IBD.\n- **Scientific Rationale:** Dual blockade offers broader suppression of pro-inflammatory pathways than monospecific agents; transcriptomic data confirm MoA.\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (SC or IV)\n- **Manufacturing Strategy:** Internal; DS at 120 mg/mL; identity via TL1A/LIGHT binding assays\n- **CMC Strategy:** Developability 2.0 applied for early risk mitigation\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** Ulcerative Colitis\n- **Development Phase:** Transitioning to Phase IIb\n- **Regulatory Designations:** SoD Q4 2024\n- **Partnerships:** In-licensed; internal development\n\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** 2035\n- **Operational Status:** PoCP and PoCC milestones in progress\n\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| Crohn’s Disease | Immunology | Preclinical | TBD | Shared MoA |\n| Expanded IBD | Immunology | Preclinical | TBD | Transcriptomic rationale |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Internal\n- **Volume:** TBD\n- **Analytical Controls:** Binding assays, endotoxin, sterility\n\n---\n\n### 8. Risks & Mitigation\n- **CMC Risk:** Glycosylation/disulfide complexity\n    - *Mitigation:* Developability 2.0 feedback loops\n\n---\n\n### 9. Clinical Trial Information\n- **Population:** Moderate–severe UC\n- **Design:** Phase IIb preparation underway"
  },
  {
    "product_code": "BI 3812465",
    "product_name": null,
    "modality_name": "Recombinant Proteins",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Ophthalmology (CI-DME)",
    "mechanism_of_action": "Bispecific FZD4/LRP5-Modulator (Wnt-/Norrin-Mimetikum) to mimic Norrin and activate Wnt/β-catenin signaling, restoring BRB integrity.",
    "short_description": "Bispecific Wnt-pathway FZD4/LRP5-Modulator for CI-DME to restore BRB integrity.",
    "description": "BI 3812465 is a bispecific Wnt-pathway agonist designed to target FZD4 and LRP5, mimicking Norrin and activating Wnt/β-catenin signaling to restore blood-retinal barrier integrity. The scientific rationale focuses on addressing vascular leakage and pericyte loss in diabetic macular edema, supported by preclinical efficacy in OIR and VEGF-leakage models. The molecule uses Surrozen's SWAP™ technology for tetravalent design, enabling complex bispecific engineering.",
    "dosage_form": "Lösung zur intravitrealen Injektion, 100 mg/mL (Single-dose Vial) + Solvent-Vial",
    "route_of_administration": "Intravitreal",
    "primary_packaging": null,
    "biel_category": null,
    "base_technology": "CHO-exprimiertes rekombinantes bispezifisches Protein (Wnt-Mimetikum)",
    "current_phase": "Phase I",
    "project_status": null,
    "lead_indication": "CI-DME",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "expected_launch_year": 2032,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": "Patients with chronic diabetic macular edema (CI-DME)",
    "clinical_trials": null,
    "operational_risks": {
      "high": [
        "Complex bispecific engineering"
      ]
    },
    "timeline_risks": {},
    "supply_chain_risks": {},
    "raw_content": "### **Comprehensive Product Profile: BI 3812465**\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3812465\n- **Product Name:** Not disclosed\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Recombinant Proteins\n- **Therapeutic Area:** Ophthalmology (CI-DME)\n- **Strategic Classification:** Bispecific Wnt-pathway agonist\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Bispecific agonist targeting FZD4 and LRP5 to mimic Norrin and activate Wnt/β-catenin signaling, restoring BRB integrity.\n- **Scientific Rationale:** Addresses vascular leakage and pericyte loss in diabetic macular edema; preclinical efficacy in OIR and VEGF-leakage models.\n\n---\n\n### 3. Formulation &amp; Manufacturing\n- **Dosage Form:** Intravitreal injection\n- **Manufacturing Strategy:** Partnership with Surrozen; SWAP™ technology for tetravalent design\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** CI-DME\n- **Development Phase:** Preclinical\n- **Partnership:** BI × Surrozen (deal value up to $600M)\n\n---\n\n### 5. Timeline &amp; Milestones\n- **Expected Launch:** 2032\n- **Operational Status:** Patent coverage secured; stability program ongoing\n---\n\n### 6. Lifecycle Management &amp; Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| CI-DME | Ophthalmology | Preclinical | 2032 | Lead |\n| Retinal Ischemia / Stroke | Ophthalmology/Neurology | Preclinical | TBD | Exploratory |\n| Wet AMD | Ophthalmology | Inactive | — | Discontinued |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Early-stage; Surrozen platform\n- **Volume:** TBD\n\n---\n\n### 8. Risks &amp; Mitigation\n- **CMC Risk:** Complex bispecific engineering\n    - *Mitigation:* SWAP™ modular design; staged tox\n---\n\n### 9. Clinical Trial Information\n- **Status:** Preclinical; no human trials yet\n\n---"
  },
  {
    "product_code": "BI 3798489",
    "product_name": "BI 3798489",
    "modality_name": "Peptides",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
    "mechanism_of_action": "NMUR2 agonist for obesity, targeting satiety circuits to reduce food intake and body weight.",
    "short_description": "NMUR2 agonist peptide for obesity.",
    "description": "BI 3798489 is a peptide therapeutic (~2.7 kDa) acting as an NMUR2 agonist to modulate satiety circuits outside the blood-brain barrier, reducing food intake and body weight. It demonstrates high selectivity for NMUR2 over NMUR1 (>162× and >1436×), minimizing GLP-1-like nausea risk. Preclinical data indicate dose-dependent inhibition of food intake and gastric emptying, supporting its potential as an obesity treatment.",
    "dosage_form": "Injectable (subcutaneous)",
    "route_of_administration": "SC injection",
    "primary_packaging": null,
    "biel_category": null,
    "base_technology": null,
    "current_phase": "Preclinical",
    "project_status": null,
    "lead_indication": "Obesity",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": {},
    "expected_launch_year": 2035,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": {},
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": "Patients with obesity; monthly dosing anticipated",
    "clinical_trials": {},
    "operational_risks": {
      "high": [
        "Limited tox data; CNS/GI effects possible"
      ]
    },
    "timeline_risks": {},
    "supply_chain_risks": {},
    "raw_content": "### **Comprehensive Product Profile: BI 3798489**\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3798489\n- **Product Name:** BI 3798489\n- **Label:** NCE (liquid)\n- **Modality Category:** Biologics\n- **Modality Name:** Peptides\n- **Therapeutic Area:** Cardiovascular-Renal-Metabolic (CRM)\n- **Strategic Classification:** Peptide – Injectable\n\n*(Source: Internal obesity strategy documents)*\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** NMUR2 agonist targeting satiety circuits outside the BBB to reduce food intake and body weight.\n- **Scientific Rationale:** High selectivity for NMUR2 over NMUR1 (>162× and >1436×) reduces risk of GLP-1-like nausea; preclinical data show dose-dependent inhibition of food intake and gastric emptying.\n- **Drug Class:** Peptide therapeutic (~2.7 kDa)\n\n*(Source: Preclinical pharmacology reports)*\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (subcutaneous)\n- **Route of Administration:** SC injection\n- **Expected Human Dose:** ~5.6 mg monthly\n- **Manufacturing Strategy:** Early-stage; DS includes non-natural amino acids\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** Obesity\n- **Development Phase:** Preclinical\n- **Regulatory Designations:** None\n\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** Post-2035 (Wave 3 obesity strategy)\n- **Operational Status:** Positioned as backup asset; SoD pending\n\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| Obesity | CRM | Preclinical | TBD | Potential for combination therapy |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Not yet established\n- **Volume:** Moderate (monthly dosing)\n\n---\n\n### 8. Risks & Mitigation\n- **CMC/Clinical Risk:** Limited tox data; CNS/GI effects possible\n    - *Mitigation:* Early selectivity screens; staged investment\n\n---\n\n### 9. Clinical Trial Information\n- **Status:** Preclinical; no human trials yet"
  },
  {
    "product_code": "BI 3797479",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Neuroscience (CIAS – Cognitive Impairment Associated with Schizophrenia)",
    "mechanism_of_action": "Catechol-O-methyltransferase (COMT) inhibitor that modulates dopamine metabolism to improve cognitive processes.",
    "short_description": "COMT inhibitor targeting dopamine metabolism for CIAS in schizophrenia.",
    "description": "BI 3797479 is a catechol-O-methyltransferase (COMT) inhibitor designed to modulate dopamine metabolism and improve cognitive processes. CIAS represents a major unmet need in schizophrenia with no approved pharmacological treatments. BI 3797479 aims to enhance dopaminergic signaling in the prefrontal cortex to improve cognition. It belongs to the COMT inhibitor drug class and is also being explored for cognitive impairment in Parkinson’s disease (CIPD).",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "primary_packaging": null,
    "biel_category": "3A",
    "base_technology": null,
    "current_phase": "Preclinical / Early Development",
    "project_status": null,
    "lead_indication": "Cognitive Impairment Associated with Schizophrenia (CIAS)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": {},
    "expected_launch_year": 2032,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": {},
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": "Adults with schizophrenia (CIAS); Parkinson’s disease (CIPD)",
    "clinical_trials": {},
    "operational_risks": {
      "high": [
        "Potential class effects (dyskinesia, hallucinations, impulse control)"
      ]
    },
    "timeline_risks": {},
    "supply_chain_risks": {},
    "raw_content": "### **Comprehensive Product Profile: BI 3797479**\n\nThis profile integrates clinical, operational, and strategic data from all available documents to provide a complete view of the asset.\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3797479\n- **Product Name:** Not yet assigned\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area:** Neuroscience (CIAS – Cognitive Impairment Associated with Schizophrenia)\n- **Strategic Classification:** Solid Oral – COMT Inhibitor\n\n*(Source: Internal neuroscience pipeline overview)*\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Catechol-O-methyltransferase (COMT) inhibitor that modulates dopamine metabolism to improve cognitive processes.\n- **Scientific Rationale:** CIAS is a major unmet need in schizophrenia with no approved pharmacological treatments. BI 3797479 aims to enhance dopaminergic signaling in the prefrontal cortex to improve cognition.\n- **Drug Class:** COMT inhibitor\n- **Exploratory Indication:** Cognitive Impairment in Parkinson’s Disease (CIPD)\n\n*(Source: Preclinical pharmacology reports and neuroscience strategy decks)*\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Not specified\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A (low pharmacological activity/toxicity)\n- **Manufacturing Strategy:** Internal; DS/DP details not yet disclosed\n\n*(Source: CMC early development documentation)*\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** Cognitive Impairment Associated with Schizophrenia (CIAS)\n- **Development Phase:** Preclinical / Early Development\n- **Regulatory Designations:** None reported\n\n*(Source: Internal pipeline tracker)*\n\n---\n\n### 5. Timeline & Milestones\n- **Expected Launch:** 2033\n- **Key Operational Status:** Stability and compatibility studies completed; Ames negative; no adverse effects in exploratory animal studies at high doses\n- **Estimated Human Dose:** 99 mg QD (CIAS); 56 mg TID (CIPD)\n\n*(Source: Preclinical development reports)*\n\n---\n\n### 6. Lifecycle Management & Planned Line Extensions\n\n| Indication | Therapeutic Area | Development Phase | Expected Launch | Notes |\n| :--- | :--- | :--- | :--- | :--- |\n| CIPD | Neuroscience | Preclinical | TBD | Dose differs; no clinical data yet |\n\n---\n\n### 7. Operational Considerations\n- **Supply Chain:** Not yet defined\n- **Volume Category:** Not specified\n\n---\n\n### 8. Risks & Mitigation\n- **Toxicology Risks:** Potential class effects (dyskinesia, hallucinations, impulse control)\n    - *Mitigation:* Early safety profiling; dose titration strategies\n---\n\n### 9. Clinical Trial Information\n- **Status:** No clinical trials initiated\n- **Planned Population:** Adults with schizophrenia (CIAS); Parkinson’s disease (CIPD)"
  },
  {
    "product_code": "BI 3820768",
    "product_name": null,
    "modality_name": "T-cell Engager",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology (Solid Tumors)",
    "mechanism_of_action": "Bispecific antibody in 2+1 format engaging ALPG on tumor cells and CD3 on T‑cells to induce targeted cytotoxicity and immune activation.",
    "short_description": "Bispecific TcE targeting ALPG and CD3 for solid tumors",
    "description": "BI 3820768 is a bispecific T-cell engager (TcE) in a 2+1 format designed to bind ALPG on tumor cells and CD3 on T-cells, inducing targeted cytotoxicity and immune activation. ALPG is highly expressed in multiple tumor types such as endometrial and ovarian cancer, with minimal expression in healthy tissues, enabling selective targeting. The 2+1 design improves tumor selectivity and reduces unspecific T-cell activation. This molecule belongs to the bispecific TcE drug class and is part of BI’s next-generation immuno-oncology strategy.",
    "dosage_form": "Injectable (IV infusion); Formulierung nicht offengelegt",
    "route_of_administration": "Intravenous (to be confirmed)",
    "primary_packaging": "Vial (reconstitution required)",
    "biel_category": null,
    "base_technology": "Bispecific IgG‑like antibody (2+1, Fc knob‑into‑hole)",
    "current_phase": "Preclinical",
    "project_status": null,
    "lead_indication": "3L Endometrial Cancer (ALPG+)",
    "submission_status": "No active submissions; FiH preparation ongoing",
    "launch_geography": "US",
    "regulatory_details": {},
    "expected_launch_year": 2031,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": {},
    "ds_volume_category": "Low volume",
    "dp_volume_category": "Low volume",
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": "Adults with ALPG+ tumors (initial focus on endometrial cancer)",
    "clinical_trials": {
      "planned": {
        "trial_name": "FiH planned April 2026",
        "indication": "Endometrial cancer (ALPG+)",
        "status": "Planned"
      }
    },
    "operational_risks": {
      "high": [
        "Biomarker testing uptake may limit patient identification"
      ]
    },
    "timeline_risks": {},
    "supply_chain_risks": {},
    "raw_content": "### **Comprehensive Product Profile: BI 3820768**\n\nThis profile integrates clinical, operational, and strategic data from all available documents to provide a complete view of the asset.\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3820768\n- **Product Name:** Not yet assigned\n- **Label:** NBE (ntm)\n- **Modality Category:** Engineered Biologics\n- **Modality Name:** T‑cell Engager\n- **Therapeutic Area:** Oncology (Solid Tumors)\n- **Strategic Classification:** NBE_NTM; Injectable\n\n*(Source: Internal oncology pipeline and TcE platform documentation)*\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Bispecific antibody in **2+1 format** engaging **ALPG** on tumor cells and **CD3** on T‑cells to induce targeted cytotoxicity and immune activation.\n- **Scientific Rationale:** ALPG is highly expressed in multiple tumor types (e.g., endometrial, ovarian) with minimal expression in healthy tissues, enabling selective targeting. The 2+1 design improves tumor selectivity and reduces unspecific T‑cell activation.\n- **Drug Class:** Bispecific T‑cell Engager (TcE)\n- **Molecular Target:** ALPG (tumor antigen) and CD3 (T‑cell receptor complex)\n\n*(Source: Preclinical oncology strategy slides and TcE engineering reports)*\n---\n\n### 3. Formulation &amp; Manufacturing\n- **Dosage Form:** Lyophilized powder for intravenous infusion\n- **Primary Packaging:** Vial (reconstitution required)\n- **Route of Administration:** Intravenous\n- **Manufacturing Strategy:** Internal; DS/DP with stringent potency and purity controls (binding assays, bioassays, orthogonal analytics)\n\n*(Source: CMC development plans and internal manufacturing readiness reports)*\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** 3L Endometrial Cancer (ALPG+)\n- **Development Phase (as of Q3 2025):** Preclinical; FiH planned for April 2026\n- **Other Indications Under Consideration:** Ovarian cancer, PDAC, CRC (biomarker‑selected ALPG+ tumors)\n\n*(Source: Oncology pipeline overview and clinical planning documents)*\n\n---\n\n### 5. Regulatory Status\n- **Designations:** None currently assigned\n- **Submission Status:** No active submissions; FiH preparation ongoing\n\n*(Source: Regulatory planning and HA engagement strategy)*\n---\n\n### 6. Timeline &amp; Milestones\n- **Expected Launch:** 2031 (Accelerated Approval scenario for 3L EC)\n- **Key Milestones:**\n    - FiH start: April 2026\n    - PoCP: Post‑FiH data readout\n    - Expansion to 2L EC and ovarian cancer: 2033–2035\n\n*(Source: Internal milestone tracker and long‑range forecast)*\n\n---\n\n### 7. Commercial &amp; Strategic Information\n- **Launch Geography:** Initial launch expected in the US; expansion to EU and Asia based on biomarker testing infrastructure\n- **Portfolio Position:** Part of BI’s next‑generation immuno‑oncology strategy leveraging T‑cell engagers for solid tumors\n\n*(Source: Oncology strategic roadmap and biomarker adoption plans)*\n\n---\n\n### 8. Operational Considerations\n- **Supply Chain Status:** Internal manufacturing; lyophilized DP supports stability and cold chain logistics\n- **Volume Category:** Low volume; biomarker‑selected patient populations\n- **Testing Requirements:** ALPG+ biomarker testing critical for patient selection; diagnostic partnerships under evaluation\n*(Source: Operational readiness and companion diagnostic planning documents)*\n\n---\n\n### 9. Clinical Trial Information\n- **Planned Clinical Design:** Step‑up dosing in FiH to mitigate CRS risk; flat maintenance dosing to minimize wastage\n- **Patient Population:** Adults with ALPG+ tumors (initial focus on endometrial cancer)\n- **Preclinical Evidence:** Strong in vitro cytotoxicity correlated with ALPG density; in vivo tumor growth inhibition with T‑cell infiltration\n*(Source: Preclinical pharmacology reports and FiH protocol draft)*\n\n---\n\n### 10. Risk Factors &amp; Mitigation\n- **Scientific/Clinical Risk:** CRS and ICANS typical of TcEs; reproductive toxicity risk due to ALPG expression in germ/placental tissues\n    - *Mitigation:* Step‑up dosing, premedication, reproductive risk management guidance\n- **CMC Risk:** Potential for mispairing and high molecular weight variants\n    - *Mitigation:* Knob‑hole Fc engineering, tight release specifications, orthogonal analytical controls\n- **Operational Risk:** Biomarker testing uptake may limit patient identification\n    - *Mitigation:* Early diagnostic partnerships and education initiatives\n\n*(Source: Risk management plans and CMC governance updates)*"
  },
  {
    "product_code": "BI 4018711",
    "product_name": "CT‑156 (working title)",
    "modality_name": "Prescription Digital Therapeutic (SaMD/PDT)",
    "process_template_name": null,
    "product_type": "DTx (SaMD)",
    "therapeutic_area": "Schizophrenia / Neuroscience (TA CREA)",
    "mechanism_of_action": "Software‑based prescription digital therapeutic designed to improve functional outcomes in schizophrenia through structured behavioral interventions delivered via a mobile platform.",
    "short_description": "Digital therapeutic to improve functional outcomes in schizophrenia via mobile behavioral interventions",
    "description": "CT‑156 is a prescription digital therapeutic (PDT) co-developed with Click Therapeutics, designed to improve functional outcomes in schizophrenia. It delivers structured behavioral interventions through a mobile platform to address functional impairment, an unmet need despite control of positive symptoms. This program complements CT‑155 for negative symptoms, forming a digital portfolio targeting distinct symptom domains in schizophrenia.",
    "dosage_form": "Software application (mobile/connected)",
    "route_of_administration": "Digital (software‑delivered intervention)",
    "primary_packaging": "Not applicable (digital product)",
    "biel_category": null,
    "base_technology": "SaMD (mobile smartphone application)",
    "current_phase": "Phase II",
    "project_status": null,
    "lead_indication": "Functional Impairment in Schizophrenia (FI SCZ)",
    "submission_status": "No active submission",
    "launch_geography": "US",
    "regulatory_details": {},
    "expected_launch_year": 2028,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": {},
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": "Patients with schizophrenia experiencing functional impairment",
    "clinical_trials": {
      "phase_1": {
        "trial_name": null,
        "indication": "Functional Impairment in Schizophrenia",
        "status": "Ongoing"
      }
    },
    "operational_risks": {
      "high": [
        "Regulatory uncertainty for PDT in functional impairment",
        "Need to demonstrate clinical differentiation over standard care",
        "Adoption and access challenges due to payer and HCP unfamiliarity"
      ]
    },
    "timeline_risks": {},
    "supply_chain_risks": {},
    "raw_content": "### **Comprehensive Product Profile: CT‑156 (BI 4018711)**\n\nThis profile integrates clinical, operational, and strategic data from all available documents to provide a complete view of the asset.\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 4018711\n- **Product Name:** CT‑156 (working title)\n- **Label:** DTx (SaMD)\n- **Modality Category:** Digital Therapeutics\n- **Modality Name:** Prescription Digital Therapeutic (SaMD/PDT)\n- **Therapeutic Area:** Schizophrenia / Neuroscience (TA CREA)\n- **Strategic Classification:** Digital (New Therapeutic Modality); first‑in‑class DTx program within BI for functional impairment in schizophrenia\n\n*(Source: Internal pipeline and schizophrenia strategy decks)*\n\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Software‑based prescription digital therapeutic designed to improve functional outcomes in schizophrenia through structured behavioral interventions delivered via a mobile platform.\n- **Scientific Rationale:** Functional impairment remains a major unmet need in schizophrenia despite control of positive symptoms. CT‑156 aims to address this gap by leveraging digital interventions to enhance real‑world functioning.\n- **Portfolio Context:** Complements CT‑155 (BI 3972080) for negative symptoms; together, these assets form a digital portfolio addressing distinct symptom domains in schizophrenia.\n\n*(Source: Internal competitive landscape and portfolio strategy documents)*\n\n---\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Software application (mobile/connected)\n- **Primary Packaging:** Not applicable (digital product)\n- **Route of Administration:** Digital (software‑delivered intervention)\n- **Manufacturing Strategy:** External co‑development partnership with Click Therapeutics for design, development, and validation of the PDT.\n\n*(Source: Partnership agreements and operational readiness materials)*\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** Functional Impairment in Schizophrenia (FI SCZ)\n- **Development Phase (as of Q3 2025):** Phase I (ongoing)\n- **Regulatory Designations:** None reported\n- **Partnerships:** Click Therapeutics (co‑development)\n\n*(Source: Internal pipeline trackers and schizophrenia landscape decks)*\n\n---\n\n### 5. Regulatory Status\n- **Designations:** None currently assigned\n- **Submission Status:** No active submission; alignment to Phase I/II evidence maturation\n\n*(Source: Regulatory planning documents)*\n\n---\n\n### 6. Timeline & Milestones\n- **Expected Launch:** 2028 (first market; subject to clinical and regulatory progress)\n- **Key Milestones:**\n    - Start of Development: Completed\n    - Phase I: Ongoing\n    - Planned Phase II/III: To be defined based on Phase I outcomes\n\n*(Source: Internal milestone tracker and potential launches overview)*\n\n---\n\n### 7. Commercial & Strategic Information\n- **Launch Geography:** Initial launch expected in the US\n- **Portfolio Position:** Positioned as a first‑in‑class PDT for functional impairment in schizophrenia, complementing CT‑155 and supporting BI’s broader CNS strategy\n*(Source: Portfolio strategy and launch planning documents)*\n\n---\n\n### 8. Operational Considerations\n- **Supply Chain Status:** Not applicable (digital product); operational focus on SaMD QMS, cybersecurity, and digital infrastructure\n- **Volume Category:** Not applicable; scale considerations relate to patient onboarding and platform capacity\n\n*(Source: Operational readiness reports)*\n\n---\n\n### 9. Clinical Trial Information\n- **Current Status:** Phase I ongoing; specific study designs and endpoints not detailed in accessible sources\n- **Development Strategy:** Evidence generation focused on functional outcomes and engagement metrics; future RWE studies anticipated to support payer and clinical adoption\n\n*(Source: Internal clinical development updates)*\n\n---\n\n### 10. Risk Factors & Mitigation\n- **Regulatory Risk:** Lack of established precedent for PDT in functional impairment\n    - *Mitigation:* Early engagement with regulators; alignment on endpoints and evidence requirements\n- **Clinical Differentiation Risk:** Need to demonstrate superiority over standard psychosocial care\n    - *Mitigation:* Focused clinical endpoints and patient experience alignment\n- **Adoption & Access Risk:** Payer and HCP unfamiliarity with PDT\n    - *Mitigation:* Planned RWE program and targeted education strategies"
  },
  {
    "product_code": "BI 3972080",
    "product_name": "CT‑155",
    "modality_name": "Prescription Digital Therapeutic (SaMD/PDT)",
    "process_template_name": null,
    "product_type": "DTx",
    "therapeutic_area": "Mental Health / CNS (CREA)",
    "mechanism_of_action": "Smartphone‑based PDT delivering evidence‑based psychosocial interventions (adaptive goal setting, cognitive restructuring, behavioral activation, social skills, positive‑affect training). Targets defeatist beliefs and promotes real‑world engagement to reduce experiential negative symptoms as an adjunct to standard‑of‑care antipsychotics.",
    "short_description": "Digital therapeutic for negative symptoms in schizophrenia",
    "description": "CT‑155 is a prescription digital therapeutic (SaMD) designed to address experiential negative symptoms in schizophrenia. It delivers evidence‑based psychosocial interventions via a smartphone app, including adaptive goal setting, cognitive restructuring, behavioral activation, and social skills training. This approach targets defeatist beliefs and promotes real‑world engagement as an adjunct to standard antipsychotic therapy, addressing a major unmet need where no FDA‑approved pharmacologic treatments exist.",
    "dosage_form": "Software / Mobile App (SaMD)",
    "route_of_administration": "Digital (smartphone‑delivered)",
    "primary_packaging": null,
    "biel_category": null,
    "base_technology": "SaMD (mobile smartphone application)",
    "current_phase": "Phase III – pivotal CONVOKE abgeschlossen; primärer Endpunkt erreicht",
    "project_status": null,
    "lead_indication": "Experiential Negative Symptoms in Schizophrenia (XNS SCZ)",
    "submission_status": "Targeted first submission: Jan 23, 2026",
    "launch_geography": "US",
    "regulatory_details": {
      "XNS_SCZ": [
        "FDA Breakthrough Device Designation"
      ]
    },
    "expected_launch_year": 2026,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": {},
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": "Adults with schizophrenia on stable antipsychotic therapy, experiencing moderate–severe experiential negative symptoms",
    "clinical_trials": {
      "phase_3": {
        "trial_name": "CONVOKE Phase III (NCT05838625, NCT06067984)",
        "indication": "Experiential negative symptoms in schizophrenia",
        "status": "Completed"
      }
    },
    "operational_risks": {
      "high": [
        "HCP and payer unfamiliarity with PDT",
        "Sustained digital adherence critical for outcomes"
      ]
    },
    "timeline_risks": {
      "medium": [
        "Novelty of PDT may prolong regulatory review"
      ]
    },
    "supply_chain_risks": {},
    "raw_content": "### **Comprehensive Product Profile: CT‑155 (BI 3972080)**\n\nThis profile integrates clinical, operational, and strategic data from all available documents to provide a complete view of the asset.\n\n---\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3972080\n- **Product Name:** CT‑155\n- **Label:** DTx (SaMD)\n- **Modality Category:** Digital Therapeutics\n- **Modality Name:** Prescription Digital Therapeutic (SaMD/PDT)\n- **Therapeutic Area:** Mental Health / CNS (CREA)\n- **Strategic Classification:** **First‑in‑Class Digital** (DTx) for experiential negative symptoms in schizophrenia (XNS SCZ)\n\n*(Source: Internal pipeline and DTx portfolio documents)*\n---\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Smartphone‑based PDT delivering evidence‑based psychosocial interventions (adaptive goal setting, cognitive restructuring, behavioral activation, social skills, positive‑affect training). Targets defeatist beliefs and promotes real‑world engagement to reduce experiential negative symptoms as an adjunct to standard‑of‑care antipsychotics.\n- **Scientific Rationale:** Addresses a major unmet need in schizophrenia—negative symptoms—where no FDA‑approved pharmacologic treatments exist. Leverages digital modality to scale validated psychosocial techniques.\n- **Drug Class:** Prescription Digital Therapeutic (SaMD)\n- **Molecular Target:** Not applicable (behavioral/psychosocial intervention)\n\n*(Source: CONVOKE Phase III topline, internal scientific rationale slides)*\n\n---\n\n### 3. Formulation &amp; Manufacturing\n- **Dosage Form:** Software / Mobile App (SaMD)\n- **Primary Packaging:** Not applicable (digital product)\n- **Route of Administration:** Digital (smartphone‑delivered)\n- **Manufacturing Strategy:** External partnership model; co‑developed with **Click Therapeutics**. BI leads clinical development and regulatory path as an investigational device.\n\n*(Source: DTx partnership agreements, internal launch readiness documents)*\n\n---\n\n### 4. Clinical Development Status\n- **Lead Indication:** Experiential Negative Symptoms in Schizophrenia (XNS SCZ)\n- **Development Phase (as of Q3 2025):**\n    - **Phase III:** Completed (CONVOKE pivotal RCT met primary endpoint in Aug 2025)\n- **Other Mentioned Programs:** Related asset CT‑156 (BI 4018711) in Phase I for functional impairment in SCZ; early exploratory concepts for adherence/functioning.\n\n*(Source: Internal pipeline overview, CONVOKE study updates)*\n\n---\n\n### 5. Regulatory Status\n- **Designations:**\n    - FDA Breakthrough Device Designation (Dec 2023)\n- **Submission Status:**\n    - Targeted first submission: **Jan 23, 2026**\n    - Expected first launch: **June 2026** (subject to regulatory review)\n\n*(Source: Regulatory planning documents, internal launch calendar)*\n---\n\n### 6. Timeline &amp; Milestones\n- **Expected Launch Dates:**\n    - **First market launch:** June 2026\n- **Key Milestones:**\n    - SoD: Nov 1, 2021\n    - PoCP: Apr 1, 2023\n    - CONVOKE Phase III topline positive: Aug 2025\n    - RWE program planned post‑launch\n\n*(Source: Internal milestone tracker, DTx program governance updates)*\n\n---\n\n### 7. Commercial &amp; Strategic Information\n- **Launch Geography:** Initial launch focused on the US market\n- **Portfolio Position:** Core component of BI’s schizophrenia strategy, complementing Iclepertin (CIAS) and CT‑156 for functional impairment. Positions BI as a leader in digital therapeutics for CNS.\n\n*(Source: Portfolio strategy decks, launch planning documents)*\n\n---\n\n### 8. Operational Considerations\n- **Supply Chain Status:** Not applicable (digital product); focus on SaMD QMS, cybersecurity, and digital infrastructure readiness\n- **Volume Category:** Not applicable; scale considerations relate to user acquisition and onboarding rather than physical manufacturing\n\n*(Source: DTx operational readiness reports)*\n\n---\n\n### 9. Clinical Trial Information\n- **Key Trials:** CONVOKE Phase III program (NCT05838625, NCT06067984)\n- **Patient Population:** Adults with schizophrenia on stable antipsychotic therapy, experiencing moderate–severe experiential negative symptoms\n- **Development Strategy:** Evidence generation includes pivotal RCT, planned RWE studies, and long‑term extension for durability\n*(Source: Clinical trial registry, internal clinical development updates)*\n\n---\n\n### 10. Risk Factors &amp; Mitigation\n- **Regulatory Risk:** Novelty of PDT in negative symptoms may prolong review\n    - *Mitigation:* Breakthrough Device Designation and robust Phase III evidence\n- **Adoption Risk:** HCP and payer unfamiliarity with PDT\n    - *Mitigation:* Targeted education, RWE program, integrated portfolio messaging\n- **Engagement Risk:** Sustained digital adherence critical for outcomes\n    - *Mitigation:* Patient‑centered design, therapeutic alliance evidence, engagement loops\n\n*(Source: Risk management plans, internal launch readiness assessments)*"
  },
  {
    "product_code": "BI 765128",
    "product_name": null,
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Eye Health",
    "mechanism_of_action": "Anti-NRP1 antibody.",
    "short_description": "Anti-NRP1 mAb for diabetic macular ischemia (DMI).",
    "description": "BI 765128 was a monoclonal antibody targeting NRP1, developed for the treatment of diabetic retinopathy. The program aimed to address vascular complications in eye health through intravitreal administration. Development was discontinued at the pre-clinical stage.",
    "dosage_form": "Injectable",
    "route_of_administration": "Intravitreal",
    "primary_packaging": "IVT_PFS (Intravitreal Pre-filled Syringe)",
    "biel_category": "2",
    "base_technology": "Mammalian",
    "current_phase": "Phase I/II (PARTRIDGE 1451-0001)",
    "project_status": "Discontinued",
    "lead_indication": "Diabetic Retinopathy (DR)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": {},
    "expected_launch_year": 2030,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": {},
    "ds_volume_category": "Very Low (<5 12k runs)",
    "dp_volume_category": "Very Low (<1 million PCS)",
    "ds_suppliers": [
      {
        "name": "Rentschler",
        "site": "N/A",
        "role": "Primary",
        "status": "qualified"
      }
    ],
    "dp_suppliers": [
      {
        "name": "Vetter",
        "site": "N/A",
        "role": "Primary",
        "status": "qualified"
      }
    ],
    "device_partners": [],
    "patient_population": "Patients with diabetic retinopathy",
    "clinical_trials": {},
    "operational_risks": {},
    "timeline_risks": {},
    "supply_chain_risks": {},
    "raw_content": "### **Definitive NME Profile: BI 765128**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 765128\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area(s):** Eye Health\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Anti-NRP1 antibody.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** IVT_PFS (Intravitreal Pre-filled Syringe)\n- **Route of Administration:** Intravitreal\n- **BIEL Category:** 2\n- **Manufacturing Strategy:** **Outsourced / Partnership-driven**\n    - **Drug Substance (DS):** **Rentschler**\n    - **Drug Product (DP):** **Vetter**\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Diabetic Retinopathy (DR)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2030)**\n\n### 6. Operational Considerations\n- **Volume Category:**\n    - **Drug Substance (DS): < 5 12k runs** (Very Low)\n    - **Drug Product (DP): < 1 million PCS** (Very Low)"
  },
  {
    "product_code": "BI 3720931",
    "product_name": null,
    "modality_name": "Gene Therapy",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Cystic Fibrosis (Respiratory)",
    "mechanism_of_action": "Third-generation, self-inactivating lentiviral vector therapy for inhaled CFTR gene delivery.",
    "short_description": "Inhaled lentiviral gene therapy for cystic fibrosis.",
    "description": "This product is a lentiviral vector-based gene therapy designed for respiratory indications. It aims to deliver functional genetic material to correct underlying defects associated with cystic fibrosis.",
    "dosage_form": "Nebulizer solution for inhalation",
    "route_of_administration": "Inhalation (nebulized)",
    "base_technology": "Third-generation self-inactivating lentiviral vector",
    "biel_category": "NCY",
    "current_phase": "Phase I/II (Lenticlair-01 FIH started Nov 2024)",
    "project_status": "Active",
    "lead_indication": "Cystic Fibrosis (CF)",
    "expected_launch_year": 2032,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "operational_risks": null,
    "timeline_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3720931**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3720931\n- **Product Name:** (Not specified)\n- **Label:** NBE (ntm)\n- **Modality Category:** Advanced Therapy\n- **Modality Name:** Gene Therapy\n- **Therapeutic Area(s):** Respiratory\n- **Strategic Classification:** (Inhalable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Lentiviral vector-based gene therapy.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Inhalable (SFInh)\n- **BIEL Category:** NCY\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Cystic Fibrosis (CF)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** Active.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2029**"
  },
  {
    "product_code": "BI 3810477",
    "product_name": null,
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Inflammation & Respiratory",
    "mechanism_of_action": "Binds a unique CTGF epitope, preventing cell surface binding and MMP7-mediated CTGF cleavage.",
    "short_description": "Humanized IgG1 mAb against CTGF for IPF/PPF.",
    "description": "This product is a monoclonal antibody designed to inhibit CTGF activity, which plays a role in fibrotic processes. It is being developed for respiratory indications, specifically IPF and PPF.",
    "dosage_form": "Injektionslösung",
    "route_of_administration": "i.v. und s.c.",
    "base_technology": "Humanisierter IgG1 mit LALA-Fc-Mutation",
    "biel_category": null,
    "current_phase": "Phase I",
    "project_status": "Active",
    "lead_indication": "IPF/PPF",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "operational_risks": null,
    "timeline_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3810477**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3810477\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area(s):** Respiratory\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Anti-CTGF antibody.\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** IPF/PPF\n- **Current Phase:** **Pre-Clinical**\n- **Status:** Active.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2034**"
  },
  {
    "product_code": "BI 765243",
    "product_name": null,
    "modality_name": "Recombinant Proteins",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Eye Health",
    "mechanism_of_action": "TrkB/anti-VEGF (bispecific).",
    "short_description": "Bispecific protein targeting TrkB and VEGF for wet AMD",
    "description": "This product is a recombinant bispecific protein targeting TrkB and VEGF pathways to address neovascular AMD. It was intended for ophthalmology indications but development has been discontinued.",
    "dosage_form": null,
    "route_of_administration": null,
    "base_technology": null,
    "biel_category": null,
    "current_phase": "Pre-Clinical",
    "project_status": "Discontinued",
    "lead_indication": "Wet AMD (nAMD)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "operational_risks": null,
    "timeline_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 765243**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 765243\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Recombinant Proteins\n- **Therapeutic Area(s):** Eye Health\n\n### 2. Scientific Profile\n- **Mechanism of Action:** TrkB/anti-VEGF (bispecific).\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Wet AMD (nAMD)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: Not specified)**"
  },
  {
    "product_code": "BI 3794407",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Inflammation & Respiratory (I&R)",
    "mechanism_of_action": "cGAS inhibitor.",
    "short_description": "Oraler cGAS-Inhibitor für SSc und Typ-I-Interferonopathien (FU zum FR).",
    "description": "BI 3794407 is a small molecule cGAS inhibitor. It was intended for systemic sclerosis (SSc), interferonopathies, and MASH. The program has been discontinued.",
    "dosage_form": "oral (Tablette/Kapsel, geplant)",
    "route_of_administration": "oral",
    "primary_packaging": null,
    "biel_category": null,
    "base_technology": "makrozyklisches NCE (QD-Profil)",
    "current_phase": "Pre-Clinical",
    "project_status": "Discontinued",
    "lead_indication": "Systemic Sclerosis (SSc)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "expected_launch_year": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": null,
    "clinical_trials": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "raw_content": "### **Definitive NME Profile: BI 3794407**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3794407\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Immunology, CRM\n\n### 2. Scientific Profile\n- **Mechanism of Action:** cGAS inhibitor.\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Systemic Sclerosis (SSc), IFN (Interferonopathies), MASH\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: Not specified)**"
  },
  {
    "product_code": "BI 3731579",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Inflammation & Respiratory / Respiratory (IPF/PPF)",
    "mechanism_of_action": "NOX4 inhibitor.",
    "short_description": "Oraler NOX4-Inhibitor zur Progressionsverlangsamung bei IPF/PPF (präklinisch).",
    "description": "BI 3731579 is a small molecule NOX4 inhibitor. It was intended for prevention of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPFp). The program has been discontinued.",
    "dosage_form": "film-coated tablet (Tablette)",
    "route_of_administration": "oral",
    "primary_packaging": "Blister; Bottle",
    "biel_category": "3A",
    "base_technology": "Spray-Dried Dispersion (HPMCAS) → Direktverpressung/Filmbeschichtung",
    "current_phase": "Pre-Clinical",
    "project_status": "Discontinued",
    "lead_indication": "IPF/PPF prevention (IPF/PPFp)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "expected_launch_year": 2033,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": null,
    "clinical_trials": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "raw_content": "### **Definitive NME Profile: BI 3731579**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3731579\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Respiratory\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** NOX4 inhibitor.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **BIEL Category:** 3A\n- **Granulation Technology:** **Organic Spray Drying; Roller Compaction**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** IPF/PPF prevention (IPF/PPFp)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2033)**"
  },
  {
    "product_code": "BI 3009947",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Immunology",
    "mechanism_of_action": "STING inhibitor.",
    "short_description": "STING inhibitor for systemic sclerosis and interferonopathies",
    "description": "BI 3009947 is a small molecule STING inhibitor intended to modulate immune signaling pathways. It was being developed for systemic sclerosis (SSc) and interferonopathies but has been discontinued.",
    "dosage_form": "Orale Darreichungsform geplant (exakte Formulierung TBD)",
    "route_of_administration": "Oral",
    "primary_packaging": null,
    "biel_category": null,
    "base_technology": null,
    "current_phase": "Pre-Clinical",
    "project_status": "Discontinued",
    "lead_indication": "Systemic Sclerosis (SSc); IFN (Interferonopathies)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "expected_launch_year": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "critical_path_item": null,
    "ppq_status": null,
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [],
    "dp_suppliers": [],
    "device_partners": [],
    "patient_population": null,
    "clinical_trials": {},
    "operational_risks": {},
    "timeline_risks": {},
    "supply_chain_risks": {},
    "raw_content": "### **Definitive NME Profile: BI 3009947**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3009947\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Immunology\n\n### 2. Scientific Profile\n- **Mechanism of Action:** STING inhibitor.\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Systemic Sclerosis (SSc), IFN (Interferonopathies)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: Not specified)**"
  },
  {
    "product_code": "BI 1810631",
    "product_name": "Zongertinib",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).",
    "short_description": "An irreversible, HER2-selective TKI designed to block uncontrolled cell production in HER2-driven cancers like NSCLC.",
    "description": "Zongertinib is an irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI). It is an oral oncology agent designed to block the HER2 pathway, which is a member of the ErbB family of receptor tyrosine kinases. Mutations in HER2 can lead to overexpression and overactivation, resulting in uncontrolled cell production, inhibition of cell death, and promotion of tumor growth. Zongertinib targets HER2 gene alterations across a number of different cancer types, with a lead indication in Non-Small Cell Lung Cancer (NSCLC).",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Spray Dried Dispersion (SDD) + Film-Coated Tablet (FCT)",
    "biel_category": "3A",
    "current_phase": "Approved/Launched (US, Accelerated Approval 08-Aug-2025)",
    "project_status": "On Track",
    "lead_indication": "Non-Small Cell Lung Cancer (NSCLC) with HER2 alterations.",
    "expected_launch_year": 2026,
    "patient_population": "Patients with HER2-driven cancers / advanced solid tumors with HER2 gene alterations.",
    "primary_packaging": "Bottle",
    "submission_status": "Submitted",
    "launch_geography": "US",
    "regulatory_details": {
      "NSCLC": [
        "Breakthrough Therapy Designation",
        "Fast Track Designation"
      ]
    },
    "ppq_status": "Completed",
    "critical_path_item": "OPS",
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": {
        "Cambrex": "completed",
        "Alphora": "ongoing"
      },
      "DP": {
        "Hovione": "completed",
        "ING": "completed"
      }
    },
    "ds_volume_category": "Low (10 - 1,000 kg)",
    "dp_volume_category": "Low (1 - 10 million PCS)",
    "ds_suppliers": [
      {
        "name": "Cambrex",
        "site": null,
        "role": "Primary",
        "status": "qualified"
      },
      {
        "name": "Alphora",
        "site": null,
        "role": "Backup",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "Hovione",
        "site": null,
        "role": "Launch",
        "status": "qualified"
      },
      {
        "name": "ING",
        "site": null,
        "role": "Launch",
        "status": "qualified"
      }
    ],
    "device_partners": null,
    "operational_risks": {
      "high": [
        "If something goes wrong, impact on submission/launch timepoint highly likely"
      ],
      "medium": [],
      "critical": []
    },
    "timeline_risks": {
      "medium": [
        "A slight shift due to clinical activities"
      ]
    },
    "supply_chain_risks": null,
    "clinical_trials": {
      "phase_1": {
        "trial_name": "NCT04886804",
        "indication": "Broader oncology development program",
        "status": null
      },
      "phase_3": {
        "trial_name": null,
        "indication": "NSCLC (1st Line)",
        "status": null
      }
    },
    "raw_content": "### **Comprehensive Product Profile: Zongertinib (BI 1810631)**\n\nThis profile integrates clinical, operational, and strategic data from all available documents to provide a complete view of the asset.\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1810631\n- **Product Name:** Zongertinib\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area:** Oncology\n- **Strategic Classification:** **Solid** (per `LuI_Strat2030_Class` in CSV)\n\n*(Source: April 2025 Pipeline, LuI Pipeline Overview.csv)*\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).\n- **Scientific Rationale:** HER2 is a member of the ErbB family of receptor tyrosine kinases. Mutations in HER2 can lead to overexpression and overactivation, resulting in uncontrolled cell production, inhibition of cell death, and promotion of tumor growth. Zongertinib is designed to block this pathway.\n- **Drug Class:** Small molecule, oral oncology agent.\n- **Molecular Target:** HER2 gene alterations across a number of different cancer types.\n\n*(Source: Oncology - Phase 3 Deep Dive Slide)*\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **Primarily outsourced via External API and Contract Development (EACD).**\n    - **Drug Substance (DS):** **Cambrex, Alphora**\n    - **Drug Product (DP):** **Hovione, ING**\n- **Granulation Technology:** **Organic Spray Drying; Roller Compaction**\n\n*(Source: LuI Pipeline Overview.csv, Launch Variance - Solids report)*\n\n### 4. Clinical Development Status\n- **Lead Indication:** Non-Small Cell Lung Cancer (NSCLC) with HER2 alterations.\n- **Development Phase by Indication (as of Q2 2025):**\n    - **Registration:** NSCLC (**2nd Line**)\n    - **Phase III:** NSCLC (**1st Line**)\n    - **Phase I:** Broader oncology development program. The Phase I trial is `NCT04886804`.\n    - **Other Mentioned Indications (from broader pipeline views):** Breast Cancer (1L & 3L+), Gastric Cancer (2L). This indicates a broad, tumor-agnostic development strategy for HER2-driven cancers.\n\n*(Source: April 2025 Pipeline, Current Pipeline (June 2024) chart, Oncology Deep Dive Slides)*\n\n### 5. Regulatory Status\n- **Designations:**\n    - Breakthrough Therapy Designation\n    - Fast Track Designation\n- **Submission Status:**\n    - **2L NSCLC:** **Status is \"Submitted\"** (as per Feb 2025 report).\n    - Launch material for the US is packaged (**\"bright stock\"**).\n    - Final shipment is dependent on regulatory approval via **PLAIR** (Pre-launch Activities Importation Request).\n\n*(Source: Our latest and upcoming OneHP Launches, Launch Variance - Solids report)*\n\n### 6. Timeline & Milestones\n- **Expected Launch Dates:**\n    - **2L NSCLC:** **\"Submitted\" status indicates a launch is imminent, likely in 2025.** (The older AD 2023 variance report showed a +66 day delay, which appears resolved).\n    - **1L NSCLC:** **Launch projected for 2026** with zero variance against the 2024 plan.\n- **Key Operational Status:**\n    - Process Performance Qualifications (PPQs) are **completed** for the initial DS/DP sites.\n    - PPQs at **further DS sites are ongoing** to build network robustness.\n\n*(Source: Launch Variance vs AD 2024 - Solids report)*\n\n### 7. Commercial & Strategic Information\n- **Launch Geography:** **Initial launch is focused on the US market.**\n- **Portfolio Position:** A key asset in Boehringer Ingelheim's \"Expanding in oncology\" strategic pillar. It represents a core part of the targeted therapy portfolio for HER2-driven cancers.\n\n*(Source: Launch Variance - Solids report, Our latest and upcoming OneHP Launches slide)*\n\n### 8. Operational Considerations\n- **Supply Chain Status:**\n    - OPS (Operations) is on the **critical path for launch timelines**.\n    - The timeline is described as **\"tight\"**.\n- **Volume Category:**\n    - **Drug Substance (DS): 10 - 1,000 kg** (Low volume)\n    - **Drug Product (DP): 1 - 10 million PCS** (Low volume)\n\n*(Source: Launch Variance - Solids report, LuI Pipeline Overview.csv)*\n\n### 9. Clinical Trial Information\n- **Key Trial:** `NCT04886804` (Phase I trial).\n- **Patient Population:** Patients with HER2-driven cancers / advanced solid tumors with HER2 gene alterations.\n- **Development Strategy:** The multi-indication program suggests a tumor-agnostic or pan-tumor development approach based on the HER2 biomarker.\n\n*(Source: Oncology Deep Dive Slides)*\n\n### 10. Risk Factors & Mitigation\n- **Timeline Risk:** A \"slight shift due to clinical activities\" was noted in a prior report.\n- **Operational Risk:** \"If something goes wrong, impact on submission/launch timepoint highly likely.\"\n- **Mitigation:**\n    - Regulatory risk is mitigated by using Breakthrough Therapy and Fast Track pathways to accelerate review.\n    - Operational risk is being managed by qualifying additional DS sites to ensure supply chain resilience.\n\n*(Source: Launch Variance vs AD 2023 - Solids report)*"
  },
  {
  "product_code": "BI 1810631_BC1",
  "product_name": "Zongertinib",
  "parent_product_code": "BI 1810631",
  "is_line_extension": true,
  "line_extension_indication": "Breast Cancer (3L+)",
  "expected_launch_year": 2029,
  "lead_indication": "Breast Cancer (Third-Line and Beyond)",
  "therapeutic_area": "Oncology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of Zongertinib for third-line and beyond breast cancer with HER2 alterations.",
  "patient_population": "Patients with HER2-driven breast cancer"
},
{
  "product_code": "BI 1810631_NSCLC2",
  "product_name": "Zongertinib",
  "parent_product_code": "BI 1810631",
  "is_line_extension": true,
  "line_extension_indication": "Adjuvant NSCLC",
  "expected_launch_year": 2031,
  "lead_indication": "Non-Small Cell Lung Cancer (Adjuvant)",
  "therapeutic_area": "Oncology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "current_phase": "Phase III",
  "short_description": "Line extension of Zongertinib for adjuvant treatment of NSCLC with HER2 alterations.",
  "patient_population": "Patients with HER2-driven NSCLC in adjuvant setting"
},
{
  "product_code": "BI 1810631_GC",
  "product_name": "Zongertinib",
  "parent_product_code": "BI 1810631",
  "is_line_extension": true,
  "line_extension_indication": "Gastric Cancer (2L)",
  "expected_launch_year": 2031,
  "lead_indication": "Gastric Cancer (Second-Line)",
  "therapeutic_area": "Oncology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of Zongertinib for second-line gastric cancer with HER2 alterations.",
  "patient_population": "Patients with HER2-driven gastric cancer"
},
{
  "product_code": "BI 1810631_BC2",
  "product_name": "Zongertinib",
  "parent_product_code": "BI 1810631",
  "is_line_extension": true,
  "line_extension_indication": "Breast Cancer (2L)",
  "expected_launch_year": 2032,
  "lead_indication": "Breast Cancer (Second-Line)",
  "therapeutic_area": "Oncology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of Zongertinib for second-line breast cancer with HER2 alterations.",
  "patient_population": "Patients with HER2-driven breast cancer"
},

  {
    "product_code": "BI 1015550",
    "product_name": "Nerandomilast",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Respiratory (IPF; PPF in Zulassung)",
    "mechanism_of_action": "An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).",
    "short_description": "Oraler PDE4B-Inhibitor, der den FVC-Rückgang bei IPF signifikant verlangsamt (Phase-3).",
    "description": "Nerandomilast is an oral, preferential inhibitor of phosphodiesterase 4B (PDE4B), representing the first molecule in a new class of PDE4B inhibitors. The primary value proposition is to develop a treatment that can potentially stop, rather than just slow, disease progression in pulmonary fibrosis (PF), addressing a major unmet medical need. Its key clinical program is the global FIBRONEER™ Phase III program, which is being conducted in more than 40 countries.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Twin Screw",
    "biel_category": "3A",
    "current_phase": "Approved/Launched (US, 09-Oct-2025, IPF)",
    "project_status": "On Track",
    "lead_indication": "Idiopathic Pulmonary Fibrosis (IPF)",
    "expected_launch_year": 2025,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": "Submitted",
    "launch_geography": "US; China",
    "regulatory_details": {
      "IPF": [
        "FDA Breakthrough Therapy Designation",
        "FDA Orphan Drug Designation"
      ]
    },
    "ppq_status": "Ongoing",
    "critical_path_item": null,
    "timeline_variance_days": -10,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": {
        "ING": "ongoing"
      },
      "DP": {
        "ING_SoL": "ongoing"
      }
    },
    "ds_volume_category": "Low (10 - 1,000 kg)",
    "dp_volume_category": "Medium (10 - 100 million PCS)",
    "ds_suppliers": [
      {
        "name": "ING",
        "site": "Ingelheim",
        "role": "Primary",
        "status": "qualified"
      }
    ],
    "dp_suppliers": [
      {
        "name": "ING_SoL",
        "site": "Ingelheim",
        "role": "Launch",
        "status": "launch_ready"
      },
      {
        "name": "Koropi",
        "site": null,
        "role": "Commercial",
        "status": "transfer_ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": {
      "high": [
        "Risk concerning titanium dioxide (TiO2) in formulation; bridging would require in-vivo BE study, adding significant workload and potential delays."
      ],
      "medium": [],
      "critical": []
    },
    "timeline_risks": {
      "medium": [
        "PPF indication has a minor (+11 days) delay noted."
      ]
    },
    "supply_chain_risks": null,
    "clinical_trials": {
      "phase_3": {
        "trial_name": "FIBRONEER™",
        "indication": "IPF",
        "status": "Ongoing"
      }
    },
    "raw_content": "### **Definitive NME Profile: Nerandomilast (BI 1015550)**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1015550\n- **Product Name:** Nerandomilast\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Respiratory, Immunology\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).\n- **Scientific Rationale & Value Proposition:**\n    - Represents the **first molecule in a new class of PDE4B inhibitors**.\n    - The stated goal is to develop a treatment that can **potentially stop, rather than just slow, disease progression** in pulmonary fibrosis (PF), addressing a major unmet need.\n- **Key Clinical Program:** The global **FIBRONEER™** Phase III program, which is being conducted in **more than 40 countries**.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** ING (Boehringer Ingelheim, Ingelheim)\n    - **Drug Product (DP):** **ING_SoL** (Launch & Innovation Solids site in Ingelheim)\n- **Granulation Technology:** **Twin Screw**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Idiopathic Pulmonary Fibrosis (IPF)\n- **Current Phase:** **Registration**\n- **Regulatory Designations (for IPF):**\n    - **FDA Breakthrough Therapy Designation**\n    - **FDA Orphan Drug Designation**\n- **Submission Status:**\n    - Initial submissions in the **US and China have already taken place**.\n    - Pre-Approval Inspection (PAI) readiness for the Ingelheim manufacturing site is confirmed.\n    - **Launch batch production is about to start.**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch (for IPF):** **2025**\n- **Timeline Variance:** The most recent operational report (*Launch Variance vs AD 2024*) shows a **-10 day positive variance (ahead of schedule)** for the related PPF indication, suggesting the program is on or ahead of its revised schedule. An older report from 2023 had shown a -41 day variance.\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Progressive Pulmonary Fibrosis (PPF)** | Respiratory | **Phase III** | **2026** | **Shares the same NME manufacturing process.** Awaiting DP transfer to the routine commercial site (**Koropi**) in 2025. Timeline has a minor (+11 days) delay noted in one report. |\n| **Systemic Sclerosis (SSc)** | Immunology | **Phase II** | 2026 (per CSV) | Uses the same solid oral formulation. No major operational changes are noted. |\n| **Pediatric (PF-ILD) PED** | Respiratory | **Pre-Clinical** | 2030 | **Significant Operational Impact:** This is a separate manufacturing stream. The DP will be outsourced to a **C(D)MO (Almac)** using a different technology (**Fluid Bed** granulation) than the NME. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** The Drug Product (DP) will be transferred from the launch site (ING_SoL) to a routine commercial site (**Koropi**) in 2025 to handle long-term supply.\n- **Volume Category:**\n    - **Drug Substance (DS): 10 - 1,000 kg** (Low)\n    - **Drug Product (DP): 10 - 100 million PCS** (Medium)\n- **Launch & Innovation Site:** **ING_LPC** (Ingelheim Launch and Pilot Plant Chemical)\n\n### 8. Risks & Mitigation\n- **Formulation Risk (Major Point from Ops Reports):**\n    - The drug has a **BCS-IV classification**, which complicates formulation changes.\n    - A risk was identified concerning the use of **titanium dioxide (TiO2)** in the formulation. Bridging between a TiO2-free and TiO2-containing version would require an in-vivo Bioequivalence (BE) study, adding significant workload and potential delays.\n- **Mitigation Strategy:**\n    - The operational team has been actively managing this risk by preparing a **\"2nd data package (TiO2+)\"** in parallel.\n    - A **Mock-PAI** for the DS was scheduled for October 2024.\n    - The primary stability studies for **both TiO2- and TiO2+ formulations were re-started** to have data ready for either scenario.\n    - PPQ for the TiO2+ formulation was scheduled for completion in September 2024.\n    - This dual-path strategy is designed to prevent a timeline impact regardless of the final regulatory decision on the formulation."
  },
  {
  "product_code": "BI 1015550_PPF",
  "product_name": "Nerandomilast",
  "parent_product_code": "BI 1015550",
  "is_line_extension": true,
  "line_extension_indication": "Progressive Pulmonary Fibrosis (PPF)",
  "expected_launch_year": 2026,
  "lead_indication": "Progressive Pulmonary Fibrosis",
  "therapeutic_area": "Respiratory",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "current_phase": "Phase III",
  "project_status": "On Track",
  "short_description": "Line extension of Nerandomilast for Progressive Pulmonary Fibrosis. Phase III development."
},
{
  "product_code": "BI 1015550_MYO",
  "product_name": "Nerandomilast",
  "parent_product_code": "BI 1015550",
  "is_line_extension": true,
  "line_extension_indication": "Myositis",
  "expected_launch_year": 2030,
  "lead_indication": "Myositis",
  "therapeutic_area": "Immunology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of Nerandomilast for Myositis indication."
},
{
  "product_code": "BI 1015550_SSC",
  "product_name": "Nerandomilast",
  "parent_product_code": "BI 1015550",
  "is_line_extension": true,
  "line_extension_indication": "Systemic Sclerosis (SSc)",
  "expected_launch_year": 2030,
  "lead_indication": "Systemic Sclerosis",
  "therapeutic_area": "Immunology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "current_phase": "Phase II",
  "project_status": "On Track",
  "short_description": "Line extension of Nerandomilast for Systemic Sclerosis. Phase II development."
},
{
  "product_code": "BI 1015550_PED",
  "product_name": "Nerandomilast",
  "parent_product_code": "BI 1015550",
  "is_line_extension": true,
  "line_extension_indication": "Pediatric Pulmonary Fibrosis (IPF; PPF PED)",
  "expected_launch_year": 2030,
  "lead_indication": "Pediatric Pulmonary Fibrosis",
  "therapeutic_area": "Respiratory",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).",
  "dosage_form": "Pediatric formulation",
  "route_of_administration": "Oral",
  "current_phase": "Pre-Clinical",
  "project_status": "On Track",
  "short_description": "Pediatric line extension of Nerandomilast for pulmonary fibrosis. Uses different manufacturing process (Fluid Bed, outsourced to Almac).",
  "base_technology": "Fluid Bed"
},

  {
    "product_code": "BI 456906",
    "product_name": "Survodutide",
    "modality_name": "Peptides",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
    "mechanism_of_action": "A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.",
    "short_description": "A GCGR/GLP-1 receptor dual agonist for people living with overweight or obesity, and for those with MASH.",
    "description": "Survodutide is a novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist. Derived from the natural gut hormone oxyntomodulin, the compound activates both GLP-1 and glucagon receptors, which are critical to controlling metabolic functions. It is being developed for people living with overweight or obesity (Body Mass Index [BMI] ≥ 27 kg/m²) and for those with Metabolic dysfunction-associated steatohepatitis (MASH).",
    "dosage_form": "Fertigspritze/Autoinjektor (in Entwicklung)",
    "route_of_administration": "Subkutan",
    "base_technology": "Synthese via SPPS (Peptid)",
    "biel_category": null,
    "current_phase": "Phase III",
    "project_status": "Delayed",
    "lead_indication": "Obesity",
    "expected_launch_year": 2027,
    "patient_population": "People living with overweight or obesity (BMI ≥ 27 kg/m²) and people living with MASH.",
    "primary_packaging": "PEN device",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": {
      "Obesity": [
        "FDA Breakthrough Therapy Designation",
        "FDA Fast Track Designation"
      ]
    },
    "ppq_status": "Halted",
    "critical_path_item": "CMC",
    "timeline_variance_days": 86,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": {
        "PPG": "halted"
      },
      "DP": null
    },
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [
      {
        "name": "PPG",
        "site": null,
        "role": null,
        "status": "halted"
      }
    ],
    "dp_suppliers": [
      {
        "name": "Thermo Fisher",
        "site": null,
        "role": null,
        "status": null
      },
      {
        "name": "ING",
        "site": null,
        "role": null,
        "status": null
      }
    ],
    "device_partners": [
      {
        "name": "Nemera",
        "device_type": "PEN",
        "role": "Primary"
      }
    ],
    "operational_risks": {
      "high": [
        "Drug substance PPQ at PPG sites is currently stopped.",
        "Development and implementation of a new 'formulation 2.0' is being executed at maximum speed with high risk."
      ],
      "medium": [],
      "critical": []
    },
    "timeline_risks": {
      "critical": [
        "Obesity indication has a +86 day delay.",
        "MASH indication has a +91 day delay."
      ]
    },
    "supply_chain_risks": null,
    "clinical_trials": {
      "phase_1": {
        "trial_name": null,
        "indication": "BI 1820237 + Survodutide (Combo)",
        "status": null
      }
    },
    "raw_content": "### **Definitive NME Profile: Survodutide (BI 456906)**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 456906\n- **Product Name:** Survodutide\n- **Label:** NCE (liquid)\n- **Modality Category:** Biologics\n- **Modality Name:** Peptides\n- **Therapeutic Area(s):** Cardiovascular-Renal-Metabolic (CRM)\n- **Strategic Classification:** NBE (New Biological Entity) - Injectable\n\n### 2. Scientific Profile\n- **Mechanism of Action:** A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.\n- **Scientific Rationale & Value Proposition:**\n    - The compound is derived from the natural gut hormone oxyntomodulin and activates both the GLP-1 and glucagon receptors, which are critical to controlling metabolic functions.\n    - It is being developed for people living with overweight or obesity (Body Mass Index [BMI] ≥ 27 kg/m²) and for those with MASH.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (assumed Subcutaneous)\n- **Primary Packaging:** Not explicitly defined, but development of a **PEN device** is a major program component.\n- **Route of Administration:** Injectable\n- **Manufacturing Strategy:** Primarily outsourced / partnership-driven.\n    - **Drug Substance (DS) & Drug Product (DP):** Sites mentioned are **PPG/Thermo Fisher/ING**.\n    - **Device Manufacturing/Assembly:** **Nemera** is the partner for the PEN device volume ramp-up. First successful assembly/packaging runs have occurred at **LPC (Launch Pilot Plant Chemical)**.\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Obesity\n- **Current Phase:** **Phase III**\n- **Regulatory Designations (for lead indication):**\n    - **FDA Breakthrough Therapy Designation**\n    - **FDA Fast Track Designation**\n- **Partnerships:** The entire program is anchored in an **external partnership or acquisition**.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch (for Obesity):** **2027**\n- **Timeline Variance:** The project has a **+86 day delay** for the Obesity indication and a **+91 day delay** for the MASH indication compared to the AD 2024 plan.\n- **Key Operational Status:**\n    - The supply chain setup for launch has been decided.\n    - **CMC (Chemistry, Manufacturing, and Controls) activities are on the critical path.**\n    - A single-use isolator test run for the PEN device, including compounding, was successful at site **F113**.\n    - The first successful verum (active drug) cartridge filling for the PEN device has been conducted.\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Metabolic dysfunction-associated steatohepatitis (MASH)** | CRM | **Phase III** | **2028** | Shares the same NME development path. Timeline is approximately one year behind the lead obesity indication. |\n| **Obesity PEN** | CRM | **Pre-Clinical** / Development | 2028 (+47 day delay) | This refers to the specific PEN device lifecycle management and scale-up, which is a critical sub-project. The **Nemera volume ramp-up scenario** is a key focus. |\n| **BI 1820237 + Survodutide (Combo)** | CRM | **Phase I** | 2030 | A new combination therapy program, indicating a next-wave lifecycle strategy. |\n| **Pediatric (Obesity, NASH) PED** | CRM | **Pre-Clinical** | 2035 | Long-term lifecycle plan for pediatric populations. No operational details are available. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** The indication and device strategy are being closely monitored. Initial contracts have been signed. The supply chain for the PEN device is a major focus, with ongoing evaluation of acceleration options.\n- **Volume Category:** Not explicitly specified, but the focus on high-volume ramp-up scenarios suggests it is anticipated to be a significant volume product.\n\n### 8. Risks & Mitigation\n- **CMC Risk (Major Point from Ops Reports):**\n    - **Drug substance PPQ (Process Performance Qualification) at PPG sites is currently stopped.** This is a significant operational issue.\n    - The **development and implementation of a new \"formulation 2.0\" is being executed at maximum speed with high risk.**\n- **Mitigation Strategy:**\n    - The operational team is focused on resolving the DS PPQ halt and de-risking the new formulation development.\n    - For the PEN device, a key mitigation is the proactive planning and decision-making for the **Nemera volume ramp-up scenario.**\n\n### 9. Clinical Trial Information\n- **Patient Population (Obesity):** People living with overweight or obesity (BMI ≥ 27 kg/m²).\n- **Patient Population (MASH):** People living with MASH."
  },
  {
  "product_code": "BI 456906_MASH1",
  "product_name": "Survodutide",
  "parent_product_code": "BI 456906",
  "is_line_extension": true,
  "line_extension_indication": "Metabolic dysfunction-associated steatohepatitis (MASH F2/F3)",
  "expected_launch_year": 2028,
  "lead_indication": "MASH F2/F3",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Peptides",
  "mechanism_of_action": "A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.",
  "dosage_form": "Fertigspritze/Autoinjektor",
  "route_of_administration": "Subkutan",
  "current_phase": "Phase III",
  "project_status": "Delayed",
  "short_description": "Line extension of Survodutide for MASH F2/F3. Shares same NME development path, approximately one year behind obesity indication.",
  "patient_population": "People living with MASH F2/F3"
},
{
  "product_code": "BI 456906_PEN",
  "product_name": "Survodutide PEN",
  "parent_product_code": "BI 456906",
  "is_line_extension": true,
  "line_extension_indication": "Obesity (PEN Device)",
  "expected_launch_year": 2028,
  "lead_indication": "Obesity",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Peptides",
  "mechanism_of_action": "A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.",
  "dosage_form": "PEN device",
  "route_of_administration": "Subkutan",
  "current_phase": "Development",
  "project_status": "On Track",
  "short_description": "PEN device line extension of Survodutide for obesity. Nemera volume ramp-up scenario is key focus.",
  "patient_population": "People living with overweight or obesity (BMI ≥ 27 kg/m²)",
  "primary_packaging": "PEN device"
},
{
  "product_code": "BI 456906_GEN2",
  "product_name": "Survodutide 2nd Gen",
  "parent_product_code": "BI 456906",
  "is_line_extension": true,
  "line_extension_indication": "Obesity (2nd Generation Drug Substance)",
  "expected_launch_year": 2029,
  "lead_indication": "Obesity",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Peptides",
  "mechanism_of_action": "A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.",
  "dosage_form": "Fertigspritze/Autoinjektor",
  "route_of_administration": "Subkutan",
  "short_description": "Second generation drug substance formulation of Survodutide. New 'formulation 2.0' development.",
  "patient_population": "People living with overweight or obesity (BMI ≥ 27 kg/m²)"
},
{
  "product_code": "BI 456906_MASH2",
  "product_name": "Survodutide",
  "parent_product_code": "BI 456906",
  "is_line_extension": true,
  "line_extension_indication": "Metabolic dysfunction-associated steatohepatitis (MASH cF4)",
  "expected_launch_year": 2030,
  "lead_indication": "MASH cF4",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Peptides",
  "mechanism_of_action": "A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.",
  "dosage_form": "Fertigspritze/Autoinjektor",
  "route_of_administration": "Subkutan",
  "short_description": "Line extension of Survodutide for compensated cirrhosis due to MASH (cF4 stage).",
  "patient_population": "People living with MASH cF4"
},
{
  "product_code": "BI 456906_PED",
  "product_name": "Survodutide PED",
  "parent_product_code": "BI 456906",
  "is_line_extension": true,
  "line_extension_indication": "Pediatric Obesity and MASH",
  "expected_launch_year": 2031,
  "lead_indication": "Pediatric Obesity; MASH",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Peptides",
  "mechanism_of_action": "A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.",
  "dosage_form": "Pediatric formulation",
  "route_of_administration": "Subkutan",
  "current_phase": "Pre-Clinical",
  "short_description": "Pediatric line extension of Survodutide for obesity and MASH in pediatric populations.",
  "patient_population": "Pediatric patients with overweight/obesity or MASH"
},
  {
    "product_code": "BI 690517",
    "product_name": "Vicadrostat",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
    "mechanism_of_action": "A novel, selective, and potent aldosterone synthase inhibitor (ASi).",
    "short_description": "An aldosterone synthase inhibitor used in combination with empagliflozin for cardiovascular and renal disease.",
    "description": "Vicadrostat is a novel, selective, and potent aldosterone synthase inhibitor (ASi). It is designed to work by effectively and sustainably inhibiting aldosterone synthase and the subsequent production of aldosterone, a hormone implicated in cardiovascular and renal disease progression. The development strategy is based on its use in combination with empagliflozin, comparing this dual-mechanism approach to empagliflozin plus placebo on top of standard of care. It is part of Boehringer Ingelheim's research and development portfolio in the cardiovascular, renal, metabolic disease area.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Twin Screw",
    "biel_category": "3A",
    "current_phase": "Phase III",
    "project_status": "On Track",
    "lead_indication": "Chronic Kidney Disease (CKD)",
    "expected_launch_year": 2028,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": "Ongoing",
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": {
        "ING": "transfer_ongoing"
      },
      "DP": {
        "ING_SoL": "transfer_ongoing"
      }
    },
    "ds_volume_category": "High (> 10 tn)",
    "dp_volume_category": "High (> 100 million PCS)",
    "ds_suppliers": [
      {
        "name": "ING",
        "site": "Ingelheim",
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "ING_SoL",
        "site": "Ingelheim",
        "role": "Launch",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: Vicadrostat (BI 690517)**\n\nThis profile treats the combination therapy with Empagliflozin as the master NME event and integrates all other indications as lifecycle extensions.\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 690517\n- **Product Name:** Vicadrostat\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Cardiovascular-Renal-Metabolic (CRM)\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** A novel, selective, and potent aldosterone synthase inhibitor (ASi).\n- **Scientific Rationale & Value Proposition:**\n    - Designed to work by effectively and sustainably inhibiting aldosterone synthase and the subsequent production of aldosterone, a hormone implicated in cardiovascular and renal disease progression.\n    - The development strategy is based on its use **in combination with empagliflozin**, comparing this dual-mechanism approach to empagliflozin plus placebo on top of standard of care.\n- **Portfolio Context:** Part of Boehringer Ingelheim's research and development portfolio in the cardiovascular, renal, metabolic disease area.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** ING (Boehringer Ingelheim, Ingelheim)\n    - **Drug Product (DP):** **ING_SoL** (Launch & Innovation Solids site in Ingelheim)\n- **Granulation Technology:** **Twin Screw**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Chronic Kidney Disease (CKD)\n- **Current Phase:** **Phase III**\n- **Regulatory Designations:** No special designations (e.g., Breakthrough Therapy) are mentioned in the provided documents.\n- **Key Development Note:** The two lead indications (CKD and HFpEF) received their Release for Full Development (RoFD) at the same time and are being developed in parallel.\n\n---\n### **5. NME Timeline & Milestones**\n\n- **Expected Launch (for CKD & HFpEF):** **2028**\n- **Timeline Variance:** The project has **zero variance** against the AD 2024 plan for both lead indications, indicating the program is on track.\n- **Key Operational Status:**\n    - The project is classified as a **high-volume product**.\n    - Network preparation is in **\"full swing\"**.\n    - The transfer of the Drug Substance (DS) and Drug Product (DP) processes to OPS (Operations) is ongoing.\n    - A packaging transfer is planned for **Q3/2025**.\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Heart Failure with Preserved Ejection Fraction (HFpEF)** | CRM | **Phase III** | **2028** | Developed in parallel with the lead CKD indication using the same combination product. Timeline and operational status are identical. |\n| **Untreated Hypertension (uHTN) + Empa** | CRM | **Pre-Clinical** | (Not specified) | A pre-clinical line extension indicating broader exploration of the combination's potential in hypertension. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** Preparation of the supply network is a high-priority, ongoing activity due to the anticipated high volume.\n- **Volume Category:**\n    - **Drug Substance (DS): > 10 tn** (High)\n    - **Drug Product (DP): > 100 million PCS** (High)\n- **Launch & Innovation Site:** **ING_LPC** (Ingelheim Launch and Pilot Plant Chemical)\n\n### 8. Risks & Mitigation\n- The provided documents do not highlight any specific, major operational risks for Vicadrostat, unlike the formulation issues with Nerandomilast or the CMC halt for Survodutide. The project appears to be proceeding on track with a focus on scaling up for a high-volume launch.\n\n### 9. Clinical Trial Information\n- **Study Design:** The trial investigates the efficacy and safety profile of vicadrostat given in combination with empagliflozin, compared to placebo and empagliflozin on top of standard of care. This design aims to isolate the additional benefit of aldosterone synthase inhibition."
  },
  {
  "product_code": "BI 690517_HFPEF",
  "product_name": "Vicadrostat + empagliflozin",
  "parent_product_code": "BI 690517",
  "is_line_extension": true,
  "line_extension_indication": "Heart Failure with Preserved Ejection Fraction (HFpEF)",
  "expected_launch_year": 2029,
  "lead_indication": "HFpEF",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "current_phase": "Phase III",
  "project_status": "On Track",
  "short_description": "Line extension of Vicadrostat in combination with empagliflozin for heart failure with preserved ejection fraction. Developed in parallel with CKD indication.",
  "patient_population": "Patients with HFpEF on top of standard of care"
},
{
  "product_code": "BI 690517_HFREF",
  "product_name": "Vicadrostat + empagliflozin",
  "parent_product_code": "BI 690517",
  "is_line_extension": true,
  "line_extension_indication": "Heart Failure with Reduced Ejection Fraction (HFrEF)",
  "expected_launch_year": 2030,
  "lead_indication": "HFrEF",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of Vicadrostat in combination with empagliflozin for heart failure with reduced ejection fraction.",
  "patient_population": "Patients with HFrEF on top of standard of care"
},
{
  "product_code": "BI 690517_CVRR",
  "product_name": "Vicadrostat + empagliflozin",
  "parent_product_code": "BI 690517",
  "is_line_extension": true,
  "line_extension_indication": "Cardiovascular-Renal Risk Reduction (CVRR)",
  "expected_launch_year": 2031,
  "lead_indication": "CVRR",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of Vicadrostat in combination with empagliflozin for cardiovascular-renal risk reduction.",
  "patient_population": "Patients at high cardiovascular-renal risk"
},
{
  "product_code": "BI 690517_PED",
  "product_name": "Vicadrostat + empagliflozin PED",
  "parent_product_code": "BI 690517",
  "is_line_extension": true,
  "line_extension_indication": "Pediatric Chronic Kidney Disease",
  "expected_launch_year": 2035,
  "lead_indication": "CKD Pediatric",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.",
  "dosage_form": "Pediatric formulation",
  "route_of_administration": "Oral",
  "current_phase": "Pre-Clinical",
  "short_description": "Pediatric line extension of Vicadrostat in combination with empagliflozin for chronic kidney disease in pediatric populations.",
  "patient_population": "Pediatric patients with CKD"
},
  {
    "product_code": "BI 685509",
    "product_name": "Avenciguat",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Immunology (Systemische Sklerose) und CRM/Nephrologie (Glomerulonephritiden)",
    "mechanism_of_action": "A soluble guanylate cyclase (sGC) activator.",
    "short_description": "An sGC activator for fibrotic and vascular diseases, with active development in Systemic Sclerosis (Phase II) and Glomerulonephritis (Phase III).",
    "description": "Avenciguat is a soluble guanylate cyclase (sGC) activator. sGC activators are part of a class of drugs that work by relaxing and widening blood vessels, which can have benefits in fibrotic and vascular diseases. The program underwent a significant strategic pivot, switching the lead indication from Chronic Kidney Disease (CKD) to Glomerulonephritis (GN).",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Direct Compression",
    "biel_category": "3B",
    "current_phase": "Phase II (SSc) and Phase III (GN)",
    "project_status": "On Track",
    "lead_indication": "Glomerulonephritis (GN)",
    "expected_launch_year": 2028,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": {
      "SSc": [
        "Fast Track Designation"
      ]
    },
    "ppq_status": "Ongoing",
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": {
        "ING": "transfer_ongoing"
      },
      "DP": {
        "ING_SoL": "transfer_ongoing"
      }
    },
    "ds_volume_category": "Medium (1 - 10 tn)",
    "dp_volume_category": "High (> 100 mio PCS)",
    "ds_suppliers": [
      {
        "name": "ING",
        "site": "Ingelheim",
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "ING_SoL",
        "site": "Ingelheim",
        "role": "Launch",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: Avenciguat (BI 685509)**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 685509\n- **Product Name:** Avenciguat\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Immunology, Cardiovascular-Renal-Metabolic (CRM)\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** A soluble guanylate cyclase (sGC) activator.\n- **Scientific Rationale & Value Proposition:** sGC activators are part of a class of drugs that work by relaxing and widening blood vessels, which can have benefits in fibrotic and vascular diseases.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3B\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** ING (Boehringer Ingelheim, Ingelheim)\n    - **Drug Product (DP):** **ING_SoL** (Launch & Innovation Solids site in Ingelheim)\n- **Granulation Technology:** **Direct Compression**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** **Glomerulonephritis (GN)**\n- **Current Phase:** **Phase II**\n- **Regulatory Designations:** **Fast Track Designation** is mentioned for the Systemic Sclerosis indication. It is unclear if this applies to the lead GN indication.\n- **Key Development Note:** A significant strategic pivot has occurred. An older pipeline view showed the lead indication as Chronic Kidney Disease (CKD), but the *Current Pipeline (June 2024)* chart and operational reports confirm a **\"Revised indication strategy, switch von CKD to GN\"**.\n\n---\n### **5. NME Timeline & Milestones**\n\n- **Expected Launch (for GN):** **2028**\n- **Timeline Basis:** The 2028 launch plan is based on achieving **conditional approval in IgAN** (IgA Nephropathy, a form of glomerulonephritis).\n- **Key Milestones & Timeline:**\n    - **Release for Full Development (RoFD) for GN:** Planned for **April 2025**.\n    - **Process Performance Qualification (PPQ) and primary stability studies:** Planned for **Q4/2025**.\n    - **Transfer to SoL (Solids manufacturing):** Starts in **June 2024**.\n    - Development of a **4mg tablet for Phase III** has been greenlighted by DEV & OPS.\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Systemic Sclerosis (SSc)** | Immunology | **Phase II** | 2026 (per CSV) | Uses the same solid oral formulation. No major operational changes noted. Granted Fast Track Designation. |\n| **Cirrhotic portal hypertension (CSPH)** | CRM | **Phase II** | 2029 (per CSV) | Uses the same solid oral formulation. The volume for this indication is projected to be higher (Medium DS, High DP) than the lead indication. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** The project is in a key transition phase with the transfer to the SoL manufacturing site beginning mid-2024. The **\"optimization of renal portfolio underway\"** note suggests active management of the development and manufacturing strategy for this asset.\n- **Volume Category (by indication):**\n    - **SSc:** DS Low (10-1,000kg), DP Medium (10-100 mio PCS)\n    - **CSPH:** DS Medium (1-10 tn), DP High (>100 mio PCS)\n\n### 8. Risks & Mitigation\n- The provided documents do not highlight any specific, major operational risks. The key challenge appears to have been the strategic pivot from CKD to GN, which has now been implemented with a clear operational plan and timeline. The proactive development of a new tablet strength for Phase III indicates the program is moving forward according to the revised strategy."
  },
  {
  "product_code": "BI 685509_SSC",
  "product_name": "Avenciguat",
  "parent_product_code": "BI 685509",
  "is_line_extension": true,
  "line_extension_indication": "Systemic Sclerosis (SSc)",
  "expected_launch_year": 2030,
  "lead_indication": "Systemic Sclerosis",
  "therapeutic_area": "Immunology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "A soluble guanylate cyclase (sGC) activator.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "current_phase": "Phase II",
  "project_status": "On Track",
  "short_description": "Line extension of Avenciguat for Systemic Sclerosis. sGC activator for fibrotic and vascular disease. Fast Track Designation granted.",
  "patient_population": "Patients with Systemic Sclerosis",
  "regulatory_details": {
    "SSc": [
      "Fast Track Designation"
    ]
  }
},
{
  "product_code": "BI 685509_PED",
  "product_name": "Avenciguat PED",
  "parent_product_code": "BI 685509",
  "is_line_extension": true,
  "line_extension_indication": "Systemic Sclerosis (Pediatric)",
  "expected_launch_year": 2034,
  "lead_indication": "Systemic Sclerosis Pediatric",
  "therapeutic_area": "Immunology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "A soluble guanylate cyclase (sGC) activator.",
  "dosage_form": "Pediatric formulation",
  "route_of_administration": "Oral",
  "current_phase": "Pre-Clinical",
  "short_description": "Pediatric line extension of Avenciguat for Systemic Sclerosis in pediatric populations.",
  "patient_population": "Pediatric patients with Systemic Sclerosis"
},
  {
    "product_code": "BI 1569912",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Mental Health",
    "mechanism_of_action": "An oral, NMDA subunit 2b-selective negative allosteric modulator (NR2B NAM).",
    "short_description": "An oral NR2B NAM designed to rapidly relieve depressive symptoms in MDD without dissociative side effects.",
    "description": "This asset is an oral, NMDA subunit 2b-selective negative allosteric modulator (NR2B NAM). It is built on the therapeutic concept of N-methyl-D-aspartate (NMDA) receptor blockers and is designed to rapidly relieve depressive symptoms in patients with Major Depressive Disorder (MDD). A key value proposition is the potential to achieve this effect without the dissociative side effects commonly associated with broader NMDA blockers.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": null,
    "biel_category": "3B",
    "current_phase": "Phase II",
    "project_status": "Discontinued",
    "lead_indication": "Major Depressive Disorder (MDD) - adjunctive therapy",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": {
      "medium": [
        "Scheduled drug classification ongoing"
      ]
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": {
      "phase_2": [
        {
          "trial_name": "NCT06558344",
          "indication": "MDD - monotherapy",
          "status": null
        },
        {
          "trial_name": "NCT06280235",
          "indication": "MDD - adjunctive therapy",
          "status": null
        }
      ]
    },
    "raw_content": "### **Definitive NME Profile: BI 1569912**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1569912\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Mental Health\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** An oral, NMDA subunit 2b-selective negative allosteric modulator (NR2B NAM).\n- **Scientific Rationale & Value Proposition:** Built on the therapeutic concept of N-methyl-D-aspartate (NMDA) receptor blockers, this asset is designed to **rapidly relieve depressive symptoms** in patients with Major Depressive Disorder (MDD), potentially **without the dissociative side effects** of broader NMDA blockers.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3B\n- **Manufacturing Strategy:** (Not specified in detail, assumed internal development at ING initially).\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Major Depressive Disorder (MDD) - adjunctive therapy\n- **Current Phase:** **Discontinued** (in Phase II)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2028)**\n- **Key Operational Status:**\n    - The product is described as **\"Highly stable\"**.\n    - Drug Substance (DS) transfer is planned for **Q4/2025**.\n    - A scheduled drug classification process is ongoing.\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- |\n| **MDD - monotherapy** | Mental Health | **Phase II** | The asset is being investigated in parallel as both a monotherapy (`NCT06558344`) and an adjunctive therapy (`NCT06280235`). |\n| **Bipolar depression** | Mental Health | **Pre-Clinical** | An earlier-stage lifecycle extension to broaden the asset's use in mood disorders. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** The significant acceleration and planned DS transfer indicate that operational planning is advancing rapidly.\n- **Volume Category:** Not explicitly specified.\n\n### 8. Risks & Mitigation\n- The primary challenge noted is administrative: the \"scheduled drug classification ongoing.\" No major operational or technical risks are highlighted. The project's \"significant acceleration\" suggests it is performing well.\n\n### 9. Clinical Trial Information\n- **Key Trials:** Phase II trials `NCT06558344` (monotherapy) and `NCT06280235` (adjunctive therapy) in people living with MDD."
  },
  {
    "product_code": "BI 1358894",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Mental Health",
    "mechanism_of_action": "TRPC4/5 inhibitor.",
    "short_description": "A TRPC4/5 inhibitor targeting ion channels implicated in mood and stress-related disorders like PTSD.",
    "description": "This asset is a TRPC4/5 inhibitor. It works by targeting ion channels TRPC4 and TRPC5, which are implicated in mood and stress-related disorders.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Fluid Bed",
    "biel_category": "3A",
    "current_phase": "Phase II",
    "project_status": "Discontinued",
    "lead_indication": "Post-Traumatic Stress Disorder (PTSD)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "High (> 10 tn)",
    "dp_volume_category": "High (> 100 million PCS)",
    "ds_suppliers": [
      {
        "name": "ING",
        "site": null,
        "role": "Primary",
        "status": "qualified"
      },
      {
        "name": "BDC",
        "site": "Biberach",
        "role": "Primary",
        "status": "qualified"
      }
    ],
    "dp_suppliers": [
      {
        "name": "ING_SoL",
        "site": "Ingelheim",
        "role": "Launch",
        "status": "qualified"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1358894**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1358894\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Mental Health\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** TRPC4/5 inhibitor.\n- **Scientific Rationale & Value Proposition:** Targeting ion channels TRPC4 and TRPC5, implicated in mood and stress-related disorders.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** ING; **BDC (Biberach Development Center)**\n    - **Drug Product (DP):** **ING_SoL**\n- **Granulation Technology:** **Fluid Bed**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Post-Traumatic Stress Disorder (PTSD)\n- **Current Phase:** **Discontinued** (Phase II)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2029)**\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Major Depressive Disorder (MDD)** | Mental Health | **Phase II** | **(was: 2029)** | Developed in parallel with PTSD using the same formulation and manufacturing process. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** DS manufacturing involves two internal sites (Ingelheim and Biberach), indicating a dual-source strategy or specialized steps at each site.\n- **Volume Category:** Anticipated to be a **high-volume product**.\n    - **Drug Substance (DS): > 10 tn** (High)\n    - **Drug Product (DP): > 100 million PCS** (High)\n\n### 8. Risks & Mitigation\n- No specific risks are highlighted in the provided documentation."
  },
  {
    "product_code": "BI 1291583",
    "product_name": "Verducatib",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Respiratory; Immunology",
    "mechanism_of_action": "Cathepsin C (CatC) inhibitor.",
    "short_description": "A CatC inhibitor for inflammatory lung conditions, targeting neutrophil serine proteases activation.",
    "description": "This asset is a Cathepsin C (CatC) inhibitor. CatC is an enzyme involved in the activation of neutrophil serine proteases, which play a role in inflammatory lung conditions. By inhibiting CatC, the drug aims to reduce inflammation in diseases such as Non-Cystic Fibrosis Bronchiectasis (NCFBE).",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Direct compression + Film-coating",
    "biel_category": "3B",
    "current_phase": "Phase III",
    "project_status": "Delayed",
    "lead_indication": "Non-Cystic Fibrosis Bronchiectasis (NCFBE)",
    "expected_launch_year": 2029,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": {
      "NCFBE": [
        "FDA Fast Track Designation"
      ]
    },
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 135,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "Low (10 - 1,000 kg)",
    "dp_volume_category": "Medium (10 - 100 million PCS)",
    "ds_suppliers": [
      {
        "name": "ING",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "ING_SoL",
        "site": null,
        "role": "Launch",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": {
      "high": [
        "The powder blend has a low ignition energy, which poses a safety risk during manufacturing.",
        "Product is moisture sensitive, shelf-life evaluations are ongoing.",
        "Need for close monitoring of nitrosamine formation."
      ],
      "medium": [],
      "critical": []
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1291583**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1291583\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Respiratory, Immunology\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Cathepsin C (CatC) inhibitor.\n- **Scientific Rationale & Value Proposition:** CatC is an enzyme involved in the activation of neutrophil serine proteases, which play a role in inflammatory lung conditions.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3B\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** ING\n    - **Drug Product (DP):** **ING_SoL**\n- **Granulation Technology:** **Roller Compaction**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Non-Cystic Fibrosis Bronchiectasis (NCFBE)\n- **Current Phase:** **Phase II**\n- **Regulatory Designations:** **FDA Fast Track Designation**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2029** (with a +135 day delay noted in the *Launch Variance vs AD 2024* report).\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Hidradenitis Suppurativa (HS)** | Immunology | **Pre-Clinical** | (Not specified) | Earlier stage lifecycle indication. |\n| **ANCA-Associated Vasculitis (ANCA-AV)** | Immunology | **Pre-Clinical** | (Not specified) | Earlier stage lifecycle indication. |\n| **Pediatric (nCFB) PED** | Respiratory | **Pre-Clinical** | 2036 | Long-term lifecycle plan for the lead indication. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** The project is in development at the launch/pilot sites.\n- **Volume Category:**\n    - **Drug Substance (DS): 10 - 1,000 kg** (Low)\n    - **Drug Product (DP): 10 - 100 million PCS** (Medium)\n- **Launch & Innovation Site:** **ING_LPC**\n\n### 8. Risks & Mitigation\n- **Manufacturing & Safety Risk (Major Point from Ops Reports):**\n    - This is a **low-volume product**.\n    - The **powder blend has a low ignition energy**, which poses a safety risk during manufacturing. Safety measures are currently under evaluation.\n    - The product is **moisture sensitive**, and shelf-life evaluations are ongoing.\n    - There is a need for **close monitoring of nitrosamine formation**."
  },
  {
  "product_code": "BI 1291583_PED",
  "product_name": "Verducatib PED",
  "parent_product_code": "BI 1291583",
  "is_line_extension": true,
  "line_extension_indication": "Pediatric Non-Cystic Fibrosis Bronchiectasis (NCFBE PED)",
  "expected_launch_year": 2031,
  "lead_indication": "Non-Cystic Fibrosis Bronchiectasis Pediatric",
  "therapeutic_area": "Respiratory; Immunology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "Cathepsin C (CatC) inhibitor.",
  "dosage_form": "Pediatric formulation",
  "route_of_administration": "Oral",
  "current_phase": "Pre-Clinical",
  "short_description": "Pediatric line extension of Verducatib for Non-Cystic Fibrosis Bronchiectasis in pediatric populations.",
  "patient_population": "Pediatric patients with Non-Cystic Fibrosis Bronchiectasis"
},
  {
    "product_code": "BI 1819479",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Respiratory; Immunology",
    "mechanism_of_action": "Lysophospholipase inhibitor / Autotaxin (ATX) inhibitor.",
    "short_description": "An Autotaxin (ATX) inhibitor targeting the generation of lysophosphatidic acid (LPA) involved in fibrosis.",
    "description": "This asset is a Lysophospholipase inhibitor, also known as an Autotaxin (ATX) inhibitor. ATX is an enzyme that generates lysophosphatidic acid (LPA), a signaling molecule involved in fibrosis. By inhibiting ATX, the drug aims to reduce fibrosis in conditions like Idiopathic Pulmonary Fibrosis.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Fluid-bed-Granulation + Endmischung, Kompression, Film-Coating",
    "biel_category": "4",
    "current_phase": "Phase II",
    "project_status": "On Track",
    "lead_indication": "Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPF)",
    "expected_launch_year": 2031,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "Low (10 - 1,000 kg)",
    "dp_volume_category": "Medium (10 - 100 million PCS)",
    "ds_suppliers": null,
    "dp_suppliers": [
      {
        "name": "Corden",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1819479**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1819479\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Respiratory, Immunology\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Lysophospholipase inhibitor / Autotaxin (ATX) inhibitor.\n- **Scientific Rationale & Value Proposition:** ATX is an enzyme that generates lysophosphatidic acid (LPA), a signaling molecule involved in fibrosis.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 4\n- **Manufacturing Strategy:** **Mixed Internal/External**\n    - **Drug Substance (DS):** (Not specified)\n    - **Drug Product (DP):** Sourced from **Corden** (a C(D)MO)\n- **Granulation Technology:** **High Shear**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPF)\n- **Current Phase:** **Phase II**\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2030** (per LuI Pipeline CSV)\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Systemic Sclerosis (SSc)** | Immunology | **Pre-Clinical** | 2033 | Uses the same formulation and outsourced manufacturing process. |\n| **Pediatric (IPF; PPF; SSc) PED**| Respiratory/Immunology | **Pre-Clinical** | 2036 | Long-term lifecycle plan for all potential indications. |\n\n---\n### 7. Operational Considerations\n- **Supply Chain Status:** The DP is developed and manufactured with a C(D)MO partner, Corden.\n- **Volume Category:**\n    - **Drug Substance (DS): 10 - 1,000 kg** (Low)\n    - **Drug Product (DP): 10 - 100 million PCS** (Medium)\n\n### 8. Risks & Mitigation\n- No specific risks are highlighted in the provided documentation."
  },
  {
    "product_code": "BI 706321",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Immunology",
    "mechanism_of_action": "RIPK2 inhibitor.",
    "short_description": "A RIPK2 inhibitor targeting the NOD signaling pathway involved in innate immunity and inflammation in IBD.",
    "description": "This asset is a RIPK2 inhibitor. RIPK2 is a kinase that plays a key role in the NOD signaling pathway, which is involved in innate immunity and inflammation, particularly in inflammatory bowel diseases.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": null,
    "biel_category": "3B",
    "current_phase": "Discontinued",
    "project_status": "Discontinued",
    "lead_indication": "Crohn's Disease (CD)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 706321**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 706321\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Immunology\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** RIPK2 inhibitor.\n- **Scientific Rationale & Value Proposition:** RIPK2 is a kinase that plays a key role in the NOD signaling pathway, which is involved in innate immunity and inflammation, particularly in inflammatory bowel diseases.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3B\n- **Manufacturing Strategy:** Development route is not specified, assumed internal.\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Crohn's Disease (CD)\n- **Current Phase:** **Discontinued** (in Phase II)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2032)**\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n\n| Indication/Formulation | Therapeutic Area | Development Phase | Expected Launch | Key Notes & Operational Impact |\n| :--- | :--- | :--- | :--- | :--- |\n| **Crohn's Disease (CD) PED** | Immunology | **Pre-Clinical** | **(was: 2033)** | Standard long-term pediatric lifecycle plan. |\n\n---\n### 7. Operational Considerations\n- **Volume Category:** Not explicitly specified.\n\n### 8. Risks & Mitigation\n- No specific risks are highlighted in the provided documentation."
  },
  {
    "product_code": "BI 3032950",
    "product_name": null,
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Immunology",
    "mechanism_of_action": "TREM-1 antagonist.",
    "short_description": "TREM-1 antibody for Ulcerative Colitis (induction i.v., maintenance s.c.); IBD program, CD in evaluation.",
    "description": "This asset is a TREM-1 antagonist. TREM-1 (Triggering Receptor Expressed on Myeloid cells 1) is a receptor involved in amplifying inflammatory responses. Antagonizing it could be beneficial in inflammatory conditions such as Crohn's Disease.",
    "dosage_form": "Intravenöse Infusion (Induktion) und subkutane Injektion (Erhaltung)",
    "route_of_administration": "IV (Induktion), SC (Erhaltung)",
    "base_technology": null,
    "biel_category": "2",
    "current_phase": "Phase II",
    "project_status": "On Track",
    "lead_indication": "Crohn's Disease (CD)",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": "PFS (Pre-filled Syringe)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3032950**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3032950\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area(s):** Immunology\n- **Strategic Classification:** (Not explicitly specified, but is an injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** TREM-1 antagonist.\n- **Scientific Rationale & Value Proposition:** TREM-1 (Triggering Receptor Expressed on Myeloid cells 1) is a receptor involved in amplifying inflammatory responses. Antagonizing it could be beneficial in inflammatory conditions.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** PFS (Pre-filled Syringe)\n- **Route of Administration:** Injectable\n- **BIEL Category:** 2\n- **Manufacturing Strategy:** Assumed internal (Mammalian cell culture).\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** General Immunology (the *Current Pipeline* chart specifies **Crohn's Disease (CD)**)\n- **Current Phase:** **Phase II** (The *April 2025 Pipeline* shows this as Phase II, while older docs show it as Phase I, confirming its progression).\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2033** (per LuI Pipeline CSV)\n\n---\n### **6. Lifecycle Management & Planned Line Extensions**\n- No line extensions are mentioned in the provided documents.\n\n---\n### 7. Operational Considerations\n- **Volume Category:** Not explicitly specified.\n\n### 8. Risks & Mitigation\n- No specific risks are highlighted in the provided documentation."
  },
  {
    "product_code": "BI 765250",
    "product_name": null,
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Immunology",
    "mechanism_of_action": "PD-1 agonist.",
    "short_description": "A PD-1 agonist antibody for immunological conditions like Systemic Sclerosis (SSc).",
    "description": "This asset is a PD-1 agonist antibody, being developed for immunological conditions such as Systemic Sclerosis (SSc).",
    "dosage_form": "IV und SC",
    "route_of_administration": "Intravenös; Subkutan",
    "base_technology": "Mammalian",
    "biel_category": "3A",
    "current_phase": "Phase I (SRD abgeschlossen; MRD laufend/PoCP-Vorbereitung)",
    "project_status": "On Track",
    "lead_indication": "Systemic Sclerosis (SSc)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Bulk_PFS (Bulk Pre-filled Syringe)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 765250**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 765250\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area(s):** Immunology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** PD-1 agonist.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Bulk_PFS (Bulk Pre-filled Syringe)\n- **Route of Administration:** Injectable (SFInj)\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** (Not specified, assumed internal)\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Systemic Sclerosis (SSc)\n- **Current Phase:** **Discontinued** (in Phase I)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2033)**\n\n### 6. Operational Considerations\n- **Project Type:** **AI (Auto-injector)** development noted in CSV."
  },
  {
    "product_code": "BI 765423",
    "product_name": null,
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Respiratory",
    "mechanism_of_action": "IL-11 blockade by binding to soluble IL-11 and preventing the IL-11/IL-11R interaction.",
    "short_description": "An anti-IL11 antibody designed to block the IL-11 cytokine implicated in fibrotic lung diseases.",
    "description": "This asset is an anti-IL11 antibody. IL-11 is a cytokine implicated in fibrotic processes. Blocking it may be beneficial in fibrotic lung diseases like IPF.",
    "dosage_form": "Injectable",
    "route_of_administration": "Injectable (SFInj)",
    "base_technology": "Mammalian",
    "biel_category": "2",
    "current_phase": "Phase I",
    "project_status": "On Track",
    "lead_indication": "Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPFr)",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": "Bulk_PFS (Bulk Pre-filled Syringe)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 765423**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 765423\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area(s):** Respiratory\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Anti-IL11 antibody.\n- **Scientific Rationale & Value Proposition:** IL-11 is a cytokine implicated in fibrotic processes. Blocking it may be beneficial in fibrotic lung diseases.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Bulk_PFS (Bulk Pre-filled Syringe)\n- **Route of Administration:** Injectable (SFInj)\n- **BIEL Category:** 2\n- **Manufacturing Strategy:** (Not specified, assumed internal)\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPFr)\n- **Current Phase:** **Phase I**\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2031**\n\n### 6. Operational Considerations\n- **Project Type:** **AI (Auto-injector)** development noted in CSV."
  },
  {
    "product_code": "BI 1703880",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Systemic 'Second-Generation' STING agonist.",
    "short_description": "Systemic STING agonist in Phase I combination trial for a broad range of solid tumors.",
    "description": "This asset is an injectable small molecule being developed for Non-Small Cell Lung Cancer (NSCLC).",
    "dosage_form": "Injectable",
    "route_of_administration": "Injectable (SFInj)",
    "base_technology": "Synthetisches niedermolekulares Molekül",
    "biel_category": "3B",
    "current_phase": "Phase I",
    "project_status": "On Track",
    "lead_indication": "Non-Small Cell Lung Cancer (NSCLC)",
    "expected_launch_year": 2032,
    "patient_population": null,
    "primary_packaging": "Vial",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "Low (10 - 1,000 kg)",
    "dp_volume_category": "Very Low (< 1 million PCS)",
    "ds_suppliers": [
      {
        "name": "C(D)MO",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "C(D)MO",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1703880**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1703880\n- **Product Name:** (Not specified)\n- **Label:** NCE (liquid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** NCE_liq. (Liquid NCE)\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Vial\n- **Route of Administration:** Injectable (SFInj)\n- **BIEL Category:** 3B\n- **Manufacturing Strategy:** **Outsourced / C(D)MO**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Non-Small Cell Lung Cancer (NSCLC)\n- **Current Phase:** **Phase I**\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2031**\n\n### 6. Operational Considerations\n- **Volume Category:**\n    - **Drug Substance (DS): 10 - 1,000 kg** (Low)\n    - **Drug Product (DP): < 1 million PCS** (Very Low)"
  },
  {
    "product_code": "BI 1831169",
    "product_name": null,
    "modality_name": "Gene Therapy",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "VSV-GP OV (Vesicular Stomatitis Virus - Glycoprotein Oncolytic Virus).",
    "short_description": "An oncolytic virus gene therapy for solid tumors like PDAC, HNSCC, and Melanoma, administered intratumorally and intravenously.",
    "description": "This asset is a VSV-GP OV (Vesicular Stomatitis Virus - Glycoprotein Oncolytic Virus), which is a form of gene therapy. It uses a modified virus to infect and kill cancer cells, and is being developed for various solid tumors.",
    "dosage_form": "Injectable",
    "route_of_administration": "Intratumoral (i.t.) und Intravenös (i.v.)",
    "base_technology": "Viral (VSV-GP platform)",
    "biel_category": "NCY",
    "current_phase": "Phase I",
    "project_status": "On Track",
    "lead_indication": "Pancreatic Ductal Adenocarcinoma (PDAC); HNSCC; Melanoma",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": "Vial",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "High (> 30 12k runs)",
    "dp_volume_category": "Very Low (< 1 million PCS)",
    "ds_suppliers": [
      {
        "name": "Lonza",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "Lonza",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1831169**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1831169\n- **Product Name:** (Not specified)\n- **Label:** NBE (ntm)\n- **Modality Category:** Advanced Therapy\n- **Modality Name:** Gene Therapy\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** VSV-GP OV (Vesicular Stomatitis Virus - Glycoprotein Oncolytic Virus).\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Vial\n- **Route of Administration:** Injectable (SFInj)\n- **BIEL Category:** NCY (New Chemical/Biological Entity)\n- **Manufacturing Strategy:** **Outsourced / Partnership-driven**\n    - **Drug Substance (DS):** **Lonza**\n    - **Drug Product (DP):** **Lonza**\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Pancreatic Ductal Adenocarcinoma (PDAC), HNSCC, Melanoma\n- **Current Phase:** **Phase I**\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2029**\n\n### 6. Operational Considerations\n- **Volume Category:**\n    - **Drug Substance (DS): > 30 12k runs** (High)\n    - **Drug Product (DP): < 1 million PCS** (Very Low)"
  },
  {
    "product_code": "BI 1821736",
    "product_name": null,
    "modality_name": "Gene Therapy",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "VSV-GP-CD80-Fc OV (Oncolytic Virus). This is a second-generation oncolytic virus, likely with enhanced immune-stimulatory properties via the CD80-Fc component.",
    "short_description": "A second-gen oncolytic virus with enhanced immune-stimulation via a CD80-Fc component for HNSCC and Melanoma, administered intratumorally and intravenously.",
    "description": "This asset is a VSV-GP-CD80-Fc Oncolytic Virus. It represents a second-generation oncolytic virus, likely engineered with enhanced immune-stimulatory properties via the inclusion of a CD80-Fc component, designed to better activate an anti-tumor immune response.",
    "dosage_form": "Injectable",
    "route_of_administration": "Intratumoral (i.t.) und Intravenös (i.v.)",
    "base_technology": "Viral (VSV-GP-CD80-Fc platform)",
    "biel_category": "NCY",
    "current_phase": "Discontinued",
    "project_status": "Discontinued",
    "lead_indication": "HNSCC; Melanoma",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Vial",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "High (> 30 12k runs)",
    "dp_volume_category": "Very Low (< 1 million PCS)",
    "ds_suppliers": [
      {
        "name": "Lonza",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "Lonza",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1821736**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1821736\n- **Product Name:** (Not specified)\n- **Label:** NBE (ntm)\n- **Modality Category:** Advanced Therapy\n- **Modality Name:** Gene Therapy\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** VSV-GP-CD80-Fc OV (Oncolytic Virus). This is a second-generation oncolytic virus, likely with enhanced immune-stimulatory properties via the CD80-Fc component.\n- **Project Note:** Listed as \"Project under revision\" in the *Current Pipeline (June 2024)* chart.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Vial\n- **Route of Administration:** Injectable (SFInj)\n- **BIEL Category:** NCY\n- **Manufacturing Strategy:** **Outsourced / Partnership-driven**\n    - **Drug Substance (DS):** **Lonza**\n    - **Drug Product (DP):** **Lonza**\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** HNSCC, Melanoma\n- **Current Phase:** **Discontinued** (Phase I)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2030)**\n\n### 6. Operational Considerations\n- **Volume Category:**\n    - **Drug Substance (DS): > 30 12k runs** (High)\n    - **Drug Product (DP): < 1 million PCS** (Very Low)"
  },
  {
    "product_code": "BI 3006337",
    "product_name": "Not disclosed; Partner-Alias: YH25724",
    "modality_name": "Recombinant Proteins",
    "process_template_name": null,
    "product_type": "NBE (Biologic)",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
    "mechanism_of_action": "GLP-1/FGF21 agonist.",
    "short_description": "Langwirksames hyFc-basiertes duales GLP-1/FGF21-Fc-Fusionsprotein für MASH.",
    "description": "This asset is a GLP-1/FGF21 dual agonist peptide, developed for the treatment of Metabolic dysfunction-associated steatohepatitis (MASH).",
    "dosage_form": "Subkutane Injektion (wöchentlich)",
    "route_of_administration": "Subkutan",
    "base_technology": "hyFc (IgD/IgG4)-Fc-Fusionsplattform",
    "biel_category": "2",
    "current_phase": "Discontinued",
    "project_status": "Discontinued",
    "lead_indication": "MASH",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Bulk_PFS (Bulk Pre-filled Syringe)",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "Very Low (< 5 12k runs)",
    "dp_volume_category": "Very Low (< 1 million PCS)",
    "ds_suppliers": [
      {
        "name": "C(D)MO",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "C(D)MO",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3006337**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3006337\n- **Product Name:** (Not specified)\n- **Label:** NCE (liquid)\n- **Modality Category:** Biologics\n- **Modality Name:** Peptides\n- **Therapeutic Area(s):** Cardiovascular-Renal-Metabolic (CRM)\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** GLP-1/FGF21 agonist.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Bulk_PFS (Bulk Pre-filled Syringe)\n- **Route of Administration:** Injectable (SFInj)\n- **BIEL Category:** 2\n- **Manufacturing Strategy:** **Outsourced / Partnership-driven**\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** MASH\n- **Current Phase:** **Discontinued** (in Phase I)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2033)**\n\n### 6. Operational Considerations\n- **Project Type:** **AI (Auto-injector)** development noted in CSV.\n- **Volume Category:**\n    - **Drug Substance (DS): < 5 12k runs** (Very Low)\n    - **Drug Product (DP): < 1 million PCS** (Very Low)"
  },
  {
    "product_code": "BI 754132",
    "product_name": "Not disclosed",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Eye Health",
    "mechanism_of_action": "TrkB activator.",
    "short_description": "A TrkB activator designed to have neuroprotective effects in the retina for conditions like Geographic Atrophy (GA), administered via intravitreal injection.",
    "description": "This asset is a TrkB activator. TrkB is a receptor for brain-derived neurotrophic factor (BDNF), and activating it may have neuroprotective effects in the retina, with a lead indication of Geographic Atrophy (GA).",
    "dosage_form": "Lösung zur intravitrealen Injektion",
    "route_of_administration": "Intravitreal",
    "base_technology": null,
    "biel_category": null,
    "current_phase": "Discontinued",
    "project_status": "Discontinued",
    "lead_indication": "Geographic Atrophy (GA)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 754132**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 754132\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Eye Health\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** TrkB activator.\n- **Scientific Rationale & Value Proposition:** TrkB is a receptor for brain-derived neurotrophic factor (BDNF), and activating it may have neuroprotective effects in the retina.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (assumed Intravitreal).\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Geographic Atrophy (GA)\n- **Current Phase:** **Discontinued** (in Phase I)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: post 2033)**"
  },
  {
    "product_code": "BI 1584862",
    "product_name": "Not disclosed",
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Eye Health",
    "mechanism_of_action": "PAFR (Platelet-Activating Factor Receptor) antagonist.",
    "short_description": "An oral PAFR antagonist for Geographic Atrophy (GA).",
    "description": "This asset is a PAFR (Platelet-Activating Factor Receptor) antagonist being developed for Geographic Atrophy (GA).",
    "dosage_form": "Film-coated tablet (10/20/50 mg)",
    "route_of_administration": "Oral",
    "base_technology": "Direct Compression",
    "biel_category": "3A",
    "current_phase": "Phase II",
    "project_status": "On Track",
    "lead_indication": "Geographic Atrophy (GA)",
    "expected_launch_year": 2032,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [
      {
        "name": "EACD",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "EACD",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1584862**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1584862\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Eye Health\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** PAFR (Platelet-Activating Factor Receptor) antagonist.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **EACD (External API and Contract Development)**\n- **Granulation Technology:** **Roller Compaction**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Geographic Atrophy (GA)\n- **Current Phase:** **Phase I**\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2032**"
  },
  {
    "product_code": "BI 1815368",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Eye Health (DME-Fokus in laufender Entwicklung)",
    "mechanism_of_action": "PKK (Plasma Kallikrein) inhibitor.",
    "short_description": "Oraler PKK-Inhibitor zur Behandlung des diabetischen Makulaödems (DME).",
    "description": "This asset is a PKK (Plasma Kallikrein) inhibitor. It is being developed for the prevention of wet age-related macular degeneration (nAMDp).",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": null,
    "biel_category": "2",
    "current_phase": "Phase II",
    "project_status": "On Track",
    "lead_indication": "Wet AMD prevention (nAMDp)",
    "expected_launch_year": 2032,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [
      {
        "name": "ING",
        "site": "Ingelheim",
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1815368**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1815368\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Eye Health\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** PKK (Plasma Kallikrein) inhibitor.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 2\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** ING\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Wet AMD prevention (nAMDp)\n- **Current Phase:** **Phase I**\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2032**"
  },
  {
  "product_code": "BI 1815368_NAMD",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 1815368",
  "is_line_extension": true,
  "line_extension_indication": "Neovascular Age-related Macular Degeneration Prevention (nAMDp)",
  "expected_launch_year": 2035,
  "lead_indication": "nAMD Prevention",
  "therapeutic_area": "Ophthalmology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "Plasma Kallikrein (PKK) inhibitor - inhibits PKK to reduce vascular permeability and inflammation in retinal diseases.",
  "dosage_form": "Powder for Oral Solution",
  "route_of_administration": "Oral",
  "short_description": "Line extension of PKK inhibitor for prevention/adjunct treatment of neovascular age-related macular degeneration.",
  "patient_population": "Patients at risk for or with early nAMD"
},
  {
    "product_code": "BI 1839100",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Respiratory",
    "mechanism_of_action": "TRPA1 inhibitor.",
    "short_description": "TRPA1-Inhibitor zur Hustenreduktion bei IPF/PPF (zusätzlich krankheitsbezogene Endpunkte in Evaluierung).",
    "description": "This asset is a TRPA1 inhibitor. TRPA1 is an ion channel involved in sensory nerve activation and is a target for treating chronic cough, particularly in the context of IPF/PPF.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": null,
    "biel_category": "3A",
    "current_phase": "Phase II",
    "project_status": "On Track",
    "lead_indication": "IPF/PPF cough",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": "Medium (10 - 100 million PCS)",
    "ds_suppliers": [
      {
        "name": "ING",
        "site": "Ingelheim",
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "ING_SoL",
        "site": "Ingelheim",
        "role": "Launch",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1839100**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1839100\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Respiratory\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** TRPA1 inhibitor.\n- **Scientific Rationale & Value Proposition:** TRPA1 is an ion channel involved in sensory nerve activation and is a target for treating chronic cough.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** ING\n    - **Drug Product (DP):** **ING_SoL**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** IPF/PPF cough\n- **Current Phase:** **Discontinued** (Phase I)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2029)**\n\n### 6. Operational Considerations\n- **Volume Category:**\n    - **Drug Product (DP): 10 - 100 million PCS** (Medium)"
  },
  {
    "product_code": "BI 754091",
    "product_name": "Ezabenlimab",
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "A humanized programmed cell death 1 (PD-1)-targeting monoclonal antibody.",
    "short_description": "PD-1 antibody as a combination backbone (e.g., with TcEs, STING-Ago., SIRPα-Antag., MDM2-Inhib.).",
    "description": "Ezabenlimab is a humanized programmed cell death 1 (PD-1)-targeting monoclonal antibody. It is a foundational immuno-oncology agent designed to block the PD-1/PD-L1 pathway, effectively \"releasing the brakes\" on the immune system to allow T-cells to attack cancer cells. It was primarily developed as a backbone for combination therapies.",
    "dosage_form": "Injectable",
    "route_of_administration": "Intravenous (IV)",
    "base_technology": "Mammalian",
    "biel_category": "3A",
    "current_phase": "Phase I/II (laufende Kombinationsprogramme)",
    "project_status": "On Track",
    "lead_indication": "IV formulation for use in Oncology combinations.",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Vial",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": "Low (6 - 15 12k runs)",
    "dp_volume_category": "Low (1 - 10 million PCS)",
    "ds_suppliers": [
      {
        "name": "Fremont",
        "site": "Fremont",
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "BC_F113",
        "site": "Biberach",
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: Ezabenlimab**\n\n### 1. Basic Product Identity\n- **Compound Code:** (Not specified, known by name)\n- **Product Name:** Ezabenlimab\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Monoclonal Antibody\n- **Therapeutic Area(s):** Oncology, Immunology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** A humanized programmed cell death 1 (PD-1)-targeting monoclonal antibody.\n- **Scientific Rationale & Value Proposition:** A foundational immuno-oncology agent designed to block the PD-1/PD-L1 pathway, \"releasing the brakes\" on the immune system to allow T-cells to attack cancer cells. Developed as a backbone for combination therapies.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Vial\n- **Route of Administration:** Intravenous (IV)\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **Internal / In-house**\n    - **Drug Substance (DS):** **Fremont**\n    - **Drug Product (DP):** **BC_F113** (Biberach)\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** IV formulation for use in Oncology combinations.\n- **Current Phase:** **Discontinued** (in Phase I)\n- **Regulatory Designations:** No special designations are mentioned.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: post 2030)**\n\n### 6. Lifecycle Management & Planned Line Extensions\n- This asset was developed as a combination partner. A key combination was with **Brigimadlin** for Sarcoma (STS), however, Brigimadlin has since been discontinued. Future combinations are likely. The April 2025 pipeline also lists a \"PD-1 antibody\" in Phase I for Immunology, which is likely this molecule.\n\n### 7. Operational Considerations\n- **Volume Category:**\n    - **Drug Substance (DS): 6 - 15 12k runs** (Low)\n    - **Drug Product (DP): 1 - 10 million PCS** (Low)"
  },
  {
    "product_code": "BI 3706674",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Nicht-kovalenter Multi-KRAS-Inhibitor, der GDP-gebundenes KRAS (wt-amp & mehrere Mutanten, inkl. G12V) bindet.",
    "short_description": "Monotherapie-Entwicklung bei KRAS-WT-Amplifikationen (GC/EC/GEJ) und KRAS-G12V (u.a. PDAC).",
    "description": "This asset is a GDP KRAS inhibitor. It is a targeted therapy aimed at a specific form of the KRAS mutation, a key driver in many cancers.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": null,
    "biel_category": "3A",
    "current_phase": "Phase I",
    "project_status": "On Track",
    "lead_indication": "Gastric Cancer (GC); Esophageal Cancer (EC); Gastroesophageal Junction Cancer (GEJC); Pancreatic Ductal Adenocarcinoma (PDAC)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [
      {
        "name": "EACD",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "EACD",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": {
      "high": [
        "Challenging cost situation; clinical efficacy under evaluation; termination likely"
      ],
      "medium": [],
      "critical": []
    },
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3706674**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3706674\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** GDP KRAS inhibitor.\n- **Scientific Rationale & Value Proposition:** A targeted therapy aimed at a specific form of the KRAS mutation, a key driver in many cancers.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Route of Administration:** Oral\n- **BIEL Category:** 3A\n- **Manufacturing Strategy:** **EACD (External API and Contract Development)**\n- **Granulation Technology:** **Organic Spray Drying; Roller Compaction**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Gastric Cancer (GC), Esophageal Cancer (EC), Gastroesophageal Junction Cancer (GEJC), Pancreatic Ductal Adenocarcinoma (PDAC)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**. The *Launch Variance vs AD 2024 - Solids* report explicitly states: \"**challenging cost situation; clinical efficacy under evaluation; termination likely**\".\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2029)**"
  },
  {
    "product_code": "BI 3018078 / BI 3024308",
    "product_name": null,
    "modality_name": "Gene Therapy",
    "process_template_name": null,
    "product_type": "NBE (Biologic)",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Heterologes Prime-Boost (ATP128 → VSV-GP128) zur Induktion tumor-spezifischer T-Zell-Immunität; in Kombination mit PD-1-Blockade (Ezabenlimab).",
    "short_description": "Therapeutischer Protein-Impfstoff (ATP128) + VSV-GP128 als Boost; Evaluierung bei MSS Stadium IV CRC in Kombi mit Ezabenlimab.",
    "description": "This asset is a combination of an antibody/protein (ATP128) and an oncolytic virus (VCV-GP128), representing a complex gene therapy approach for Colorectal Cancer (CRC).",
    "dosage_form": "Injectable",
    "route_of_administration": "Parenteral (kombinationsabhängig)",
    "base_technology": "KISIMA® rekombinantes Protein-Impfstoff-Platform + VSV-GP viraler Vektor",
    "biel_category": "4",
    "current_phase": "Phase Ib",
    "project_status": "On Track",
    "lead_indication": "Colorectal Cancer (CRC)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3018078 & BI 3024308**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3018078 / BI 3024308\n- **Product Name:** (Not specified)\n- **Label:** NBE (ntm)\n- **Modality Category:** Advanced Therapy\n- **Modality Name:** Gene Therapy\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** ATP128 + VCV-GP128 (combination of an antibody/protein and an oncolytic virus).\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable (SFInj)\n- **BIEL Category:** 4\n- **Biological Production System:** Microbial\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Colorectal Cancer (CRC)\n- **Current Phase:** **Pre-Clinical** (though older chart shows it in Phase I, latest position is Pre-Clinical).\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2032)**"
  },
  {
    "product_code": "BI 3810539",
    "product_name": null,
    "modality_name": "Monoclonal Antibody",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "DLL3 ADC (Antibody-Drug Conjugate).",
    "short_description": "A DLL3-targeting Antibody-Drug Conjugate (ADC) for Triple-Negative Breast Cancer (TNBC) and Small Cell Lung Cancer (SCLC).",
    "description": "This asset is a DLL3 Antibody-Drug Conjugate (ADC). It targets the DLL3 protein, which is expressed on certain tumor cells, to deliver a potent cytotoxic payload.",
    "dosage_form": "Injectable",
    "route_of_administration": null,
    "base_technology": null,
    "biel_category": null,
    "current_phase": "Discontinued",
    "project_status": "Discontinued",
    "lead_indication": "Triple-Negative Breast Cancer (TNBC); Small Cell Lung Cancer (SCLC)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": "Vial",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3810539**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3810539\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Engineered Biologics\n- **Modality Name:** ADC\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** DLL3 ADC (Antibody-Drug Conjugate).\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Vial\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Triple-Negative Breast Cancer (TNBC), Small Cell Lung Cancer (SCLC)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2033)**"
  },
  {
    "product_code": "BI 3810944",
    "product_name": null,
    "modality_name": "Recombinant Proteins",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Kollagenbindende, MMP9-aktivierte IL-12-Prodrug (ODC).",
    "short_description": "Systemische ODC-IL12-Prodrug; sentinel indication Melanoma.",
    "description": "This asset is an ODC-IL12 therapy, likely a cytokine-based treatment designed to stimulate an immune response against cancer, with a lead indication in Melanoma.",
    "dosage_form": "Injectable",
    "route_of_administration": null,
    "base_technology": null,
    "biel_category": null,
    "current_phase": "Phase I",
    "project_status": "On Track",
    "lead_indication": "Melanoma",
    "expected_launch_year": 2032,
    "patient_population": null,
    "primary_packaging": "Vial",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3810944**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3810944\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Recombinant Proteins\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** ODC-IL12 (likely a cytokine-based therapy).\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Vial\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Melanoma\n- **Current Phase:** **Pre-Clinical**\n- **Status:** Active.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2031**"
  },
  {
    "product_code": "BI 3907074 / BI 3907075 / BI 3720590",
    "product_name": null,
    "modality_name": "Gene Therapy",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Kombination aus KISIMA-Impfkonstrukten (ATP150/152) und VSV-GP onkolytischem Vektor (154).",
    "short_description": "A complex gene therapy combining multiple proteins (KISIMA) and an oncolytic virus for Pancreatic Ductal Adenocarcinoma (PDAC).",
    "description": "This asset is a complex combination therapy, ATP150/ATP152 + VSV-GP154, which likely involves multiple therapeutic proteins and an oncolytic virus. It represents an advanced gene therapy approach for Pancreatic Ductal Adenocarcinoma (PDAC).",
    "dosage_form": "Injectable",
    "route_of_administration": null,
    "base_technology": "Viral (VSV-GP) + Impfplattform (KISIMA®)",
    "biel_category": "NCY",
    "current_phase": "Pre-Clinical",
    "project_status": "On Track",
    "lead_indication": "Pancreatic Ductal Adenocarcinoma (PDAC)",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": "Vial",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3907074, BI 3907075, BI 3720590**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3907074 / BI 3907075 / BI 3720590\n- **Product Name:** (Not specified)\n- **Label:** NBE (ntm)\n- **Modality Category:** Advanced Therapy\n- **Modality Name:** Gene Therapy\n- **Therapeutic Area(s):** Oncology\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** ATP150/ATP152 + VSV-GP154 (A complex combination, likely involving multiple proteins and an oncolytic virus).\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **Primary Packaging:** Vial\n- **BIEL Category:** NCY\n- **Biological Production System:** Microbial\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Pancreatic Ductal Adenocarcinoma (PDAC)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** Active.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2031**"
  },
  {
    "product_code": "BI 3802876",
    "product_name": null,
    "modality_name": "Recombinant Proteins",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
    "mechanism_of_action": "FAP-verankerter TRAILR2-Agonist (HSC-Ziel).",
    "short_description": "A FAP-TRAILR2 agonist for MASH.",
    "description": "This asset is a FAP-TRAILR2 agonist being developed for Metabolic dysfunction-associated steatohepatitis (MASH).",
    "dosage_form": "Injectable (IV)",
    "route_of_administration": "IV",
    "base_technology": "Mammalian",
    "biel_category": "3A",
    "current_phase": "Phase I (laufend)",
    "project_status": "On Track",
    "lead_indication": "MASH",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3802876**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3802876\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Recombinant Proteins\n- **Therapeutic Area(s):** Cardiovascular-Renal-Metabolic (CRM)\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** FAP-TRAILR2 agonist.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **BIEL Category:** 3A\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** MASH\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2035)**"
  },
  {
    "product_code": "BI 3804379",
    "product_name": null,
    "modality_name": "Recombinant Proteins",
    "process_template_name": null,
    "product_type": "NBE",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
    "mechanism_of_action": "Anti-IL11",
    "short_description": "An injectable recombinant protein for MASH.",
    "description": "This asset is an injectable recombinant protein developed for Metabolic dysfunction-associated steatohepatitis (MASH).",
    "dosage_form": "Injectable",
    "route_of_administration": "SC und IV",
    "base_technology": "Mammalian",
    "biel_category": "NCY",
    "current_phase": "Phase I (laufend)",
    "project_status": "On Track",
    "lead_indication": "MASH",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3804379**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3804379\n- **Product Name:** (Not specified)\n- **Label:** NBE\n- **Modality Category:** Biologics\n- **Modality Name:** Recombinant Proteins\n- **Therapeutic Area(s):** Cardiovascular-Renal-Metabolic (CRM)\n- **Strategic Classification:** (Injectable)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** Not specified.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Injectable\n- **BIEL Category:** NCY\n- **Biological Production System:** Mammalian\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** MASH\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2037)**"
  },
  {
    "product_code": "BI 3906517",
    "product_name": null,
    "modality_name": "Peptides",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
    "mechanism_of_action": "Triple-Agonist an GCGR/GIPR/GLP-1R.",
    "short_description": "Long-acting Triple-Agonist für Adipositas.",
    "description": "This asset is an LG3RA (Leptin receptor antagonist), a small molecule being developed for the treatment of Obesity.",
    "dosage_form": "Injectable",
    "route_of_administration": "SC (subkutan)",
    "base_technology": "Long-acting Peptid mit Half-Life-Extension (HLE)",
    "biel_category": null,
    "current_phase": "Preclinical",
    "project_status": "On Track",
    "lead_indication": "Obesity",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3906517**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3906517\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Cardiovascular-Renal-Metabolic (CRM)\n\n### 2. Scientific Profile\n- **Mechanism of Action:** LG3RA (Leptin receptor antagonist).\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Obesity\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: Not specified)**"
  },
  {
    "product_code": "BI 1356225",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Mental Health (Impulsivity in Substance Use Disorder)",
    "mechanism_of_action": "GOAT (Ghrelin O-acyltransferase) inhibitor.",
    "short_description": "Oraler GOAT-Inhibitor zur Reduktion von Impulsivität bei Opioid-Use-Disorder; Präzisionspsychiatrie-Ansatz.",
    "description": "This asset is a GOAT (Ghrelin O-acyltransferase) inhibitor, a small molecule developed for indications in both mental health and metabolism, including Impulsivity, Substance Use Disorder, and Obesity.",
    "dosage_form": "Film-coated tablets (2.5/10 mg); Powder for oral solution (20 mg)",
    "route_of_administration": "Oral",
    "base_technology": "Solid oral DP (film-coated tablet; PfOS verfügbar)",
    "biel_category": null,
    "current_phase": "Phase I",
    "project_status": "On Track",
    "lead_indication": "Impulsivity/Substance Use Disorder (SuD) / Obesity",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 1356225**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 1356225\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Mental Health, CRM\n\n### 2. Scientific Profile\n- **Mechanism of Action:** GOAT (Ghrelin O-acyltransferase) inhibitor.\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Impulsivity/Substance Use Disorder (SuD) / Obesity\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2034)**"
  },
  {
    "product_code": "BI 3031185",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Mental Health",
    "mechanism_of_action": "mGluR4 NAM (Negative Allosteric Modulator).",
    "short_description": "An mGluR4 Negative Allosteric Modulator for Impulsivity.",
    "description": "This asset is an mGluR4 Negative Allosteric Modulator (NAM), a small molecule being developed for the treatment of Impulsivity.",
    "dosage_form": "Orale solide Darreichungsform (geplant)",
    "route_of_administration": "Oral",
    "base_technology": null,
    "biel_category": "3A",
    "current_phase": "Pre-Clinical",
    "project_status": "On Track",
    "lead_indication": "Impulsivity",
    "expected_launch_year": 2034,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3031185**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3031185\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Mental Health\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** mGluR4 NAM (Negative Allosteric Modulator).\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **BIEL Category:** 3A\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Impulsivity\n- **Current Phase:** **Pre-Clinical**\n- **Status:** Active.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2035**"
  },
  {
    "product_code": "BI 3776528",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Mental Health – Cognitive impairment in PSD/Schizophrenia",
    "mechanism_of_action": "SSTR4 agonist.",
    "short_description": "Oraler SSTR4-Agonist zur Behandlung kognitiver Beeinträchtigung in PSD/SCZ-Spektrum.",
    "description": "This asset is an SSTR4 agonist, a small molecule developed for Cognitive Impairment Post-Stroke Depression (CI PSD).",
    "dosage_form": "Capsules (1-40 mg; mit Placebo-Match)",
    "route_of_administration": "Oral",
    "base_technology": "Orale Kapseln",
    "biel_category": null,
    "current_phase": "Phase I (laufend)",
    "project_status": "On Track",
    "lead_indication": "Cognitive Impairment Post-Stroke Depression (CI PSD)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3776528**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3776528\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Mental Health\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** SSTR4 agonist.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **BIEL Category:** (not specified)\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Cognitive Impairment Post-Stroke Depression (CI PSD)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: 2036)**"
  },
  {
    "product_code": "BI 3793898",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Mental Health",
    "mechanism_of_action": "mGluR3 PAM (Positive Allosteric Modulator).",
    "short_description": "An mGluR3 Positive Allosteric Modulator for Cognitive Impairment Associated with Schizophrenia (CIAS).",
    "description": "This asset is an mGluR3 Positive Allosteric Modulator (PAM), a small molecule developed for Cognitive Impairment Associated with Schizophrenia (CIAS).",
    "dosage_form": null,
    "route_of_administration": null,
    "base_technology": null,
    "biel_category": null,
    "current_phase": "Pre-Clinical (post-SoD)",
    "project_status": "On Track",
    "lead_indication": "Cognitive Impairment Associated with Schizophrenia (CIAS)",
    "expected_launch_year": null,
    "patient_population": null,
    "primary_packaging": null,
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": null,
    "dp_suppliers": null,
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3793898**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3793898\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Mental Health\n\n### 2. Scientific Profile\n- **Mechanism of Action:** mGluR3 PAM (Positive Allosteric Modulator).\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Cognitive Impairment Associated with Schizophrenia (CIAS)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** **Discontinued**\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **(was: Not specified)**"
  },
  {
    "product_code": "BI 3000202",
    "product_name": null,
    "modality_name": "Small Molecule",
    "process_template_name": null,
    "product_type": "NME",
    "therapeutic_area": "Immunology",
    "mechanism_of_action": "cGAS inhibitor.",
    "short_description": "Oraler cGAS-Inhibitor für SSc und monogene Interferonopathien; potenziell krankheitsmodifizierend.",
    "description": "This asset is a cGAS inhibitor, a small molecule developed for immunological conditions like Systemic Sclerosis (SSc) and Interferonopathies (IFN).",
    "dosage_form": "Film-coated tablets (1/10/25/50 mg)",
    "route_of_administration": "Oral",
    "base_technology": null,
    "biel_category": null,
    "current_phase": "Phase I",
    "project_status": "On Track",
    "lead_indication": "Systemic Sclerosis (SSc) / IFN (Interferonopathies)",
    "expected_launch_year": 2032,
    "patient_population": null,
    "primary_packaging": "Blister; Bottle",
    "submission_status": null,
    "launch_geography": null,
    "regulatory_details": null,
    "ppq_status": null,
    "critical_path_item": null,
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": null,
    "ds_volume_category": null,
    "dp_volume_category": null,
    "ds_suppliers": [
      {
        "name": "C(D)MO",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "dp_suppliers": [
      {
        "name": "C(D)MO",
        "site": null,
        "role": "Primary",
        "status": "ongoing"
      }
    ],
    "device_partners": null,
    "operational_risks": null,
    "timeline_risks": null,
    "supply_chain_risks": null,
    "clinical_trials": null,
    "raw_content": "### **Definitive NME Profile: BI 3000202**\n\n### 1. Basic Product Identity\n- **Compound Code:** BI 3000202\n- **Product Name:** (Not specified)\n- **Label:** NCE (solid)\n- **Modality Category:** Traditional\n- **Modality Name:** Small Molecule\n- **Therapeutic Area(s):** Immunology\n- **Strategic Classification:** Solid\n\n### 2. Scientific Profile\n- **Mechanism of Action:** cGAS inhibitor.\n\n### 3. Formulation & Manufacturing\n- **Dosage Form:** Tablet\n- **Primary Packaging:** Blister; Bottle\n- **Manufacturing Strategy:** Development with a **C(D)MO**.\n- **Granulation Technology:** **Roller Compaction**\n\n### 4. Lead NME Development & Regulatory Status\n- **Lead NME Indication:** Systemic Sclerosis (SSc) / IFN (Interferonopathies)\n- **Current Phase:** **Pre-Clinical**\n- **Status:** Active.\n\n### 5. NME Timeline & Milestones\n- **Expected Launch:** **2033**"
  },
  {
  "product_code": "BI 764532",
  "product_name": "Obrixtamig",
  "modality_name": "T-cell Engager",
  "product_type": "NME",
  "therapeutic_area": "Oncology",
  "mechanism_of_action": "Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung.",
  "short_description": "Bispezifischer Antikörper für neuroendokrine Karzinome. Lead indication: 2L epNEC als Monotherapie.",
  "description": "Obrixtamig ist ein DLL3/CD3 T-Zell-Engager zur Behandlung von aggressiven neuroendokrinen Karzinomen. Bindet DLL3 auf Tumorzellen und CD3 auf T-Zellen zur Aktivierung des Immunsystems gegen DLL3-exprimierende Tumorzellen. Step-up-Strategie von 2L zu 1L in epNEC und SCLC.",
  "dosage_form": "Pulver für Lösung zur Infusion",
  "route_of_administration": "Intravenös und subkutan",
  "current_phase": "Phase II",
  "project_status": "On Track",
  "lead_indication": "Extra-pulmonale neuroendokrine Karzinome (2L epNEC)",
  "expected_launch_year": 2027,
  "patient_population": "Patienten mit DLL3-positiven neuroendokrinen Karzinomen",
  "primary_packaging": "Glasvial (30 mg/Vial)",
  "submission_status": null,
  "launch_geography": "US; Germany; Japan; China",
  "ppq_status": "DS abgeschlossen, DP geplant Q4/2025",
  "is_nme": true
},
{
  "product_code": "BI 764532_SCLC",
  "product_name": "Obrixtamig",
  "parent_product_code": "BI 764532",
  "is_line_extension": true,
  "line_extension_indication": "Small Cell Lung Cancer (1L SCLC)",
  "expected_launch_year": 2029,
  "lead_indication": "Extensive-Stage Small Cell Lung Cancer (First-Line)",
  "therapeutic_area": "Oncology",
  "modality_name": "T-cell Engager",
  "mechanism_of_action": "Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung.",
  "dosage_form": "Pulver für Lösung zur Infusion",
  "route_of_administration": "Intravenös und subkutan",
  "current_phase": "Phase III",
  "project_status": "On Track",
  "short_description": "Line extension of Obrixtamig for first-line ES-SCLC. Combination therapy with Pt/Etoposid + Immunotherapy (Dareon™-9).",
  "patient_population": "Patients with extensive-stage small cell lung cancer, first-line treatment"
},
{
  "product_code": "BI 764532_EPNEC",
  "product_name": "Obrixtamig",
  "parent_product_code": "BI 764532",
  "is_line_extension": true,
  "line_extension_indication": "Extra-pulmonale neuroendokrine Karzinome (1L epNEC)",
  "expected_launch_year": 2029,
  "lead_indication": "Extra-pulmonale neuroendokrine Karzinome (First-Line)",
  "therapeutic_area": "Oncology",
  "modality_name": "T-cell Engager",
  "mechanism_of_action": "Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung.",
  "dosage_form": "Pulver für Lösung zur Infusion",
  "route_of_administration": "Intravenös und subkutan",
  "current_phase": "Phase Ib/III",
  "project_status": "On Track",
  "short_description": "Line extension of Obrixtamig for first-line epNEC. Combination therapy with Pt/Etoposid (Dareon™-7).",
  "patient_population": "Patients with extra-pulmonary neuroendocrine carcinomas, first-line treatment"
},
{
  "product_code": "BI 764198",
  "product_name": "Not disclosed",
  "modality_name": "Small Molecule",
  "product_type": "NME",
  "therapeutic_area": "Nephrology",
  "mechanism_of_action": "TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.",
  "short_description": "TRPC6 inhibitor for renal diseases, primarily targeting FSGS (Focal Segmental Glomerulosclerosis).",
  "description": "BI 764198 is a TRPC6 inhibitor developed for treatment of renal diseases. TRPC6 plays a role in podocyte function and its dysregulation is implicated in proteinuric kidney diseases. Lead indication is FSGS with Proof-of-Concept achieved and accelerated development path.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "current_phase": "Phase II",
  "project_status": "On Track",
  "lead_indication": "Focal Segmental Glomerulosclerosis (FSGS)",
  "expected_launch_year": 2031,
  "patient_population": "Patients with FSGS and other proteinuric kidney diseases",
  "therapeutic_area": "Nephrology / Renal",
  "is_nme": true
},
{
  "product_code": "BI 764198_DMD",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 764198",
  "is_line_extension": true,
  "line_extension_indication": "Duchenne Muscular Dystrophy (DMD)",
  "expected_launch_year": 2032,
  "lead_indication": "Duchenne Muscular Dystrophy",
  "therapeutic_area": "Neuromuscular Disorders",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of TRPC6 inhibitor for Duchenne Muscular Dystrophy.",
  "patient_population": "Patients with Duchenne Muscular Dystrophy"
},
{
  "product_code": "BI 764198_PODO",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 764198",
  "is_line_extension": true,
  "line_extension_indication": "Podocytopathies",
  "expected_launch_year": 2034,
  "lead_indication": "Podocytopathies",
  "therapeutic_area": "Nephrology / Renal",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of TRPC6 inhibitor for podocyte-related kidney diseases.",
  "patient_population": "Patients with podocytopathies"
},
{
  "product_code": "BI 764198_PED",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 764198",
  "is_line_extension": true,
  "line_extension_indication": "Focal Segmental Glomerulosclerosis (FSGS) Pediatric",
  "expected_launch_year": 2035,
  "lead_indication": "FSGS Pediatric",
  "therapeutic_area": "Nephrology / Renal",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.",
  "dosage_form": "Pediatric formulation",
  "route_of_administration": "Oral",
  "current_phase": "Pre-Clinical",
  "short_description": "Pediatric line extension of TRPC6 inhibitor for FSGS in pediatric populations.",
  "patient_population": "Pediatric patients with FSGS"
},
{
  "product_code": "BI 764524",
  "product_name": "Not disclosed",
  "modality_name": "Monoclonal Antibody",
  "product_type": "NME",
  "therapeutic_area": "Ophthalmology",
  "mechanism_of_action": "Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology.",
  "short_description": "Anti-Sema3A antibody for retinal diseases, primarily targeting Diabetic Retinopathy.",
  "description": "BI 764524 is an anti-Semaphorin 3A antibody developed for retinal health applications. SEMA3A is implicated in neurodegeneration and vascular dysfunction in diabetic retinopathy and related retinal diseases.",
  "dosage_form": "Solution for injection",
  "route_of_administration": "Intravitreal",
  "current_phase": "Phase II",
  "project_status": "On Track",
  "lead_indication": "Diabetic Retinopathy (DR)",
  "expected_launch_year": 2031,
  "patient_population": "Patients with Diabetic Retinopathy",
  "is_nme": true
},
{
  "product_code": "BI 764524_DME",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 764524",
  "is_line_extension": true,
  "line_extension_indication": "Center-Involved Diabetic Macular Edema (CI-DME)",
  "expected_launch_year": 2032,
  "lead_indication": "CI-DME",
  "therapeutic_area": "Ophthalmology",
  "modality_name": "Monoclonal Antibody",
  "mechanism_of_action": "Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology.",
  "dosage_form": "Solution for injection",
  "route_of_administration": "Intravitreal",
  "short_description": "Line extension of anti-Sema3A antibody for center-involved diabetic macular edema.",
  "patient_population": "Patients with CI-DME"
},
{
  "product_code": "BI 764524_IRVO",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 764524",
  "is_line_extension": true,
  "line_extension_indication": "Macular Edema following Retinal Vein Occlusion (iRVO)",
  "expected_launch_year": 2032,
  "lead_indication": "iRVO",
  "therapeutic_area": "Ophthalmology",
  "modality_name": "Monoclonal Antibody",
  "mechanism_of_action": "Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology.",
  "dosage_form": "Solution for injection",
  "route_of_administration": "Intravitreal",
  "short_description": "Line extension of anti-Sema3A antibody for macular edema following retinal vein occlusion.",
  "patient_population": "Patients with iRVO"
},
{
  "product_code": "BI 770371",
  "product_name": "Not disclosed",
  "modality_name": "Recombinant Proteins",
  "product_type": "NME",
  "therapeutic_area": "Oncology",
  "mechanism_of_action": "SIRPα antagonist - blocks the Signal Regulatory Protein alpha (SIRPα) to enhance macrophage-mediated tumor cell phagocytosis.",
  "short_description": "SIRPα antagonist for oncology, primarily targeting Head and Neck Squamous Cell Carcinoma.",
  "description": "BI 770371 is a SIRPα antagonist that works by blocking the 'don't eat me' signal between cancer cells and immune cells, thereby enhancing the immune system's ability to recognize and destroy tumor cells through macrophage-mediated phagocytosis.",
  "dosage_form": "Solution for infusion",
  "route_of_administration": "Intravenous",
  "primary_packaging": "Vial (500 mg/vial, 50 mg/mL)",
  "current_phase": "Phase I/II",
  "project_status": "On Track",
  "lead_indication": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
  "expected_launch_year": 2032,
  "patient_population": "Patients with HNSCC",
  "is_nme": true
},
{
  "product_code": "BI 770371_MASH",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 770371",
  "is_line_extension": true,
  "line_extension_indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
  "expected_launch_year": 2034,
  "lead_indication": "MASH",
  "therapeutic_area": "Hepatology / CRM",
  "modality_name": "Recombinant Proteins",
  "mechanism_of_action": "SIRPα antagonist - blocks the Signal Regulatory Protein alpha (SIRPα) to enhance macrophage-mediated phagocytosis and reduce inflammation.",
  "dosage_form": "Solution for infusion",
  "route_of_administration": "Intravenous",
  "short_description": "Line extension of SIRPα antagonist for MASH, targeting inflammatory pathways in metabolic liver disease.",
  "patient_population": "Patients with MASH"
},
{
  "product_code": "BI 3000202_DF4",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 3000202",
  "is_line_extension": true,
  "line_extension_indication": "Type I Interferonopathy (dF4)",
  "expected_launch_year": 2032,
  "lead_indication": "Type I Interferonopathy dF4",
  "therapeutic_area": "Immunology / Autoinflammatory Diseases",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of cGAS inhibitor for type I interferonopathy dF4 indication.",
  "patient_population": "Patients with type I interferonopathy dF4"
},
{
  "product_code": "BI 3000202_SSC",
  "product_name": "Not disclosed",
  "parent_product_code": "BI 3000202",
  "is_line_extension": true,
  "line_extension_indication": "Systemic Sclerosis (SSc)",
  "expected_launch_year": 2035,
  "lead_indication": "Systemic Sclerosis",
  "therapeutic_area": "Immunology",
  "modality_name": "Small Molecule",
  "mechanism_of_action": "cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling and fibrosis.",
  "dosage_form": "Tablet",
  "route_of_administration": "Oral",
  "short_description": "Line extension of cGAS inhibitor for Systemic Sclerosis.",
  "patient_population": "Patients with Systemic Sclerosis"
},
{
  "product_code": "BI XXXXX",
  "product_name": "Tenecteplase",
  "modality_name": "Recombinant Proteins",
  "product_type": "NME",
  "therapeutic_area": "Neurology / Stroke",
  "mechanism_of_action": "Tissue Plasminogen Activator - recombinant fibrin-specific thrombolytic agent that converts plasminogen to plasmin.",
  "short_description": "Tissue plasminogen activator for acute ischemic stroke in extended time window (4.5-24h). Single-bolus administration offers practical advantage over alteplase.",
  "description": "Tenecteplase (TNK) is a modified tissue plasminogen activator with fibrin-specificity and longer half-life than alteplase. TRACE-5 study (Phase III, BAO ≤24h) demonstrated improved reperfusion and better mRS distribution without safety disadvantage (sICH 1.8% vs 3.0%). ESO/AHA guidelines support TNK 0.25 mg/kg as alternative to alteplase with easy single-bolus administration.",
  "dosage_form": "Solution for injection",
  "route_of_administration": "Intravenous (single bolus)",
  "current_phase": "Phase III",
  "project_status": "On Track",
  "lead_indication": "Acute Ischemic Stroke (AIS) in extended time window (4.5-24h)",
  "expected_launch_year": 2029,
  "patient_population": "Patients with acute ischemic stroke, including basilar artery occlusion (BAO) up to 24 hours",
  "clinical_trials": {
    "phase_3": {
      "trial_name": "TRACE-5",
      "indication": "BAO ≤24h",
      "status": "Completed"
    }
  },
  "regulatory_details": {
    "AIS": [
      "ESO/AHA Guidelines support TNK as alternative to alteplase"
    ]
  },
  "is_nme": true
},
{
  "product_code": "BI 765049",
  "product_name": "Not disclosed",
  "modality_name": "T-cell Engager",
  "product_type": "NME",
  "therapeutic_area": "Oncology",
  "mechanism_of_action": "B7-H6/CD3 bispecific T-cell engager - binds B7-H6 on tumor cells and CD3 on T-cells to activate immune response against cancer cells.",
  "short_description": "B7-H6/CD3 bispecific T-cell engager for colorectal cancer. First-in-human Phase I as monotherapy and in combination with PD-1 inhibitor ezabenlimab.",
  "description": "BI 765049 is a B7-H6/CD3 bispecific IgG-like T-cell engager developed for gastrointestinal malignancies with focus on colorectal cancer. Preclinical studies demonstrated activity in CRC models. Currently in Phase I development as monotherapy and in combination with anti-PD-1 antibody ezabenlimab.",
  "dosage_form": "Solution for infusion",
  "route_of_administration": "Intravenous",
  "current_phase": "Phase I",
  "project_status": "On Track",
  "lead_indication": "Colorectal Cancer (CRC)",
  "expected_launch_year": 2030,
  "patient_population": "Patients with advanced colorectal cancer and other gastrointestinal malignancies",
  "clinical_trials": {
    "phase_1": {
      "trial_name": "First-in-Human",
      "indication": "CRC/GI Malignancies",
      "status": "Ongoing (Mono + Combo with ezabenlimab)"
    }
  },
  "is_nme": true
},
{
  "product_code": "BI 765179",
  "product_name": "Not disclosed",
  "modality_name": "Monoclonal Antibody",
  "product_type": "NME",
  "therapeutic_area": "Oncology",
  "mechanism_of_action": "CD137-FAP bispecific agonist antibody - provides tumor-restricted CD137 activation through cancer-associated fibroblast (CAF) targeting via FAP.",
  "short_description": "CD137-FAP bispecific agonist antibody for head and neck squamous cell carcinoma. Phase Ib in combination with pembrolizumab for first-line PD-L1+ HNSCC.",
  "description": "BI 765179 is a CD137-FAP bispecific agonist antibody designed to selectively activate CD137 (4-1BB) costimulatory signaling in the tumor microenvironment. By targeting FAP (fibroblast activation protein) on cancer-associated fibroblasts, it restricts immune activation to tumor tissue, minimizing systemic toxicity. Phase Ia completed; currently in Phase Ib combination study with pembrolizumab for first-line PD-L1+ HNSCC.",
  "dosage_form": "Solution for infusion",
  "route_of_administration": "Intravenous",
  "current_phase": "Phase Ib",
  "project_status": "On Track",
  "lead_indication": "Head and Neck Squamous Cell Carcinoma (HNSCC), First-Line PD-L1+",
  "expected_launch_year": 2031,
  "patient_population": "Patients with PD-L1+ head and neck squamous cell carcinoma, first-line treatment",
  "clinical_trials": {
    "phase_1a": {
      "trial_name": null,
      "indication": "Dose escalation",
      "status": "Completed"
    },
    "phase_1b": {
      "trial_name": null,
      "indication": "1L PD-L1+ HNSCC + Pembrolizumab",
      "status": "Ongoing"
    }
  },
  "is_nme": true
},
{
  "product_code": "BI 765845",
  "product_name": "Not disclosed (internal: G5 MYDGF)",
  "modality_name": "Recombinant Proteins",
  "product_type": "NME",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "mechanism_of_action": "Myeloid-Derived Growth Factor (MYDGF) - recombinant protein designed for tissue protection and cardiac repair post-STEMI. Reduces cardiomyocyte apoptosis from reperfusion injury and promotes angiogenesis for improved cardiac regeneration.",
  "short_description": "Recombinant MYDGF protein for acute STEMI treatment. Single IV bolus in catheterization lab during primary PCI to reduce reperfusion injury.",
  "description": "BI 765845 is a modified human MYDGF (Myeloid-Derived Growth Factor) recombinant protein therapeutic developed for ST-elevation myocardial infarction (STEMI). Administered as a single intravenous dose during primary PCI in the acute setting to provide tissue protection by reducing apoptosis and promoting cardiac repair through angiogenesis. Phase II initiated October 2023.",
  "dosage_form": "Solution for infusion (acute bolus)",
  "route_of_administration": "Intravenous (Single-Dose in catheterization lab)",
  "current_phase": "Phase II",
  "project_status": "On Track",
  "lead_indication": "ST-Elevation Myocardial Infarction (STEMI)",
  "expected_launch_year": 2031,
  "patient_population": "STEMI patients with complete or near-complete coronary occlusion undergoing primary PCI",
  "operational_risks": {
    "high": [
      "Extremely short time window for preparation and administration (≤3-5 minutes) in acute emergency setting poses significant operational challenge"
    ]
  },
  "is_nme": true
},
{
  "product_code": "BI 3940749",
  "product_name": "Not disclosed",
  "modality_name": "Small Molecule",
  "product_type": "NME",
  "therapeutic_area": "Oncology",
  "mechanism_of_action": "KRAS multi-degrader (PROTAC) - uses CRBN-mediated ubiquitination to induce proteasomal degradation of KRAS proteins. Pan-KRAS approach targeting multiple KRAS mutations through targeted protein degradation via E3 ligase CRBN.",
  "short_description": "Pan-KRAS PROTAC degrader for solid tumors with KRAS drivers (PDAC, NSCLC, CRC). Oral small molecule using CRBN E3 ligase for protein degradation.",
  "description": "BI 3940749 is a pan-KRAS PROTAC (Proteolysis Targeting Chimera) degrader that induces KRAS protein degradation through CRBN-mediated ubiquitination and proteasomal breakdown. Unlike mutation-specific inhibitors, this multi-KRAS approach targets various KRAS mutations. Start-of-Development achieved October 7, 2024. First-in-Human planned Q2 2026. Internal NDA target Q4 2030. Oral formulation using ASD/SDD or CAPS technology.",
  "dosage_form": "Tablet (oral formulation using spray-dried dispersion or CAPS technology)",
  "route_of_administration": "Oral",
  "base_technology": "Spray Dried Dispersion (SDD) or CAPS (pH-dependent solubility)",
  "current_phase": "Pre-Clinical (FIH Q2/2026)",
  "project_status": "On Track",
  "lead_indication": "Solid tumors with KRAS drivers (CRC, NSCLC, PDAC)",
  "expected_launch_year": 2031,
  "patient_population": "Patients with KRAS-driven solid tumors including pancreatic cancer, non-small cell lung cancer, and colorectal cancer",
  "operational_risks": {
    "high": [
      "Highly competitive field with multiple pan-KRAS programs in Phase 1-3 (e.g., RMC-6236) creating differentiation and timeline pressure"
    ]
  },
  "ds_suppliers": [
    {
      "name": "ING",
      "site": null,
      "role": "Primary",
      "status": "development"
    }
  ],
  "is_nme": true
},
{
  "product_code": "BI 3923948",
  "product_name": "Not disclosed",
  "modality_name": "Gene Therapy",
  "product_type": "NME",
  "therapeutic_area": "Oncology",
  "mechanism_of_action": "VSV-GP oncolytic virus with GSDME-IL12 payload - combines productive tumor cell infection and oncolysis (VSV-GP platform) with GSDME-mediated immunogenic cell death and IL-12-driven CD8+ T-cell activation to 'heat up' the tumor microenvironment.",
  "short_description": "Oncolytic virus platform for triple-negative breast cancer. VSV-GP vector carrying GSDME and IL-12 transgenes for combined oncolysis and immune activation.",
  "description": "BI 3923948 is an oncolytic virus therapeutic based on the VSV-GP (Vesicular Stomatitis Virus - Glycoprotein) platform, genetically modified to express GSDME (gasdermin E) for enhanced immunogenic cell death and IL-12 for potent T-cell activation. The combination aims to transform 'cold' tumors into 'hot' tumors with robust immune infiltration. IMPD (Investigational Medicinal Product Dossier) submitted to EU authorities September 2025. Boehringer Ingelheim has established strategic VSV Manufacturing & Analytics capabilities and internal GMP plasmid supply (since February 2025) through the Viral Therapeutics Center (VTC).",
  "dosage_form": "Solution for injection/infusion",
  "route_of_administration": "To be determined (likely intratumoral or intravenous)",
  "current_phase": "Pre-Clinical (IMPD submitted September 2025)",
  "project_status": "On Track",
  "lead_indication": "Triple-Negative Breast Cancer (TNBC)",
  "expected_launch_year": 2034,
  "patient_population": "Patients with triple-negative breast cancer",
  "operational_risks": {
    "medium": [
      "Dependency on vector and plasmid supply chains requires robust internal VSV manufacturing and analytics platform",
      "Complex CMC requirements for oncolytic virus production"
    ]
  },
  "is_nme": true
},
{
  "product_code": "BI 3034701",
  "product_name": "Not disclosed",
  "modality_name": "Peptides",
  "product_type": "NME",
  "therapeutic_area": "Cardiovascular-Renal-Metabolic (CRM)",
  "mechanism_of_action": "Triple agonist targeting GLP-1R, GIPR, and NPY2R - simultaneous activation of three receptors involved in appetite regulation and energy homeostasis for weight management. Long-acting peptide therapeutic.",
  "short_description": "Long-acting triple agonist peptide (GLP-1R/GIPR/NPY2R) for obesity. Phase I study evaluating safety, tolerability, and pharmacokinetics in people with overweight/obesity.",
  "description": "BI 3034701 is a novel long-acting peptide therapeutic that simultaneously activates three receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and NPY2R (neuropeptide Y receptor 2). This triple agonist approach differentiates it from dual agonists like Survodutide (GCGR/GLP-1R). Phase I trial initiated July 2024 to assess safety, tolerability, and pharmacokinetics in adults with overweight or obesity (BMI ≥27 kg/m²).",
  "dosage_form": "Long-acting injectable formulation (specific device not disclosed)",
  "route_of_administration": "Subcutaneous (presumed, typical for long-acting peptides)",
  "current_phase": "Phase I",
  "project_status": "On Track",
  "lead_indication": "Obesity (Overweight/Obesity BMI ≥27 kg/m²)",
  "expected_launch_year": 2032,
  "patient_population": "Adults with overweight or obesity (BMI ≥27 kg/m²)",
  "regulatory_details": {
    "Obesity": [
      "Part of BI's next-generation CRM obesity portfolio strategy"
    ]
  },
  "is_nme": true
},
{
  "product_code": "BI 771716",
  "product_name": "Not disclosed",
  "modality_name": "Monoclonal Antibody",
  "product_type": "NME",
  "therapeutic_area": "Ophthalmology / Retinal Health",
  "mechanism_of_action": "Anti-C3/C3b antibody fragment (scFv) - highly specific single-chain variable fragment targeting C3 and C3b, inhibiting complement activation via all three pathways (classical, lectin, and alternative).",
  "short_description": "Anti-C3 antibody fragment (scFv) for Geographic Atrophy secondary to AMD. Intravitreal injection showing >90% reduction of free C3 in aqueous humor. Phase II VERDANT study active comparing q4w and q8w regimens vs pegcetacoplan.",
  "description": "BI 771716 is a highly specific single-chain variable fragment (scFv) antibody targeting complement C3/C3b for treatment of Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). The molecule inhibits complement activation across all three pathways. Phase I (NCT06006585) completed May 2024 demonstrated >90% reduction of free C3 in aqueous humor by Day 29 with no drug-related SAEs. Phase II VERDANT study (NCT06722157) initiated 2025 is a randomized, double-masked, active-controlled trial comparing BI 771716 q4w and q8w regimens against pegcetacoplan q4w. Start-of-Development achieved July 1, 2021.",
  "dosage_form": "Solution for injection (single-dose vial, 150 mg/mL, 150 mg/vial)",
  "route_of_administration": "Intravitreal injection (IVT)",
  "base_technology": "Single-chain variable fragment (scFv) format",
  "primary_packaging": "Single-dose vial (current development; PFS platform under portfolio-wide evaluation)",
  "current_phase": "Phase II",
  "project_status": "On Track",
  "lead_indication": "Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD)",
  "expected_launch_year": 2030,
  "patient_population": "Patients with Geographic Atrophy secondary to AMD",
  "clinical_trials": {
    "phase_1": {
      "trial_name": "1497-0001 (FIH)",
      "nct_id": "NCT06006585",
      "indication": "Safety, Tolerability, PK/TE of IVT BI 771716",
      "status": "Completed (Oct 2023 - May 2024)",
      "design": "Open-label, non-randomized, SRD + MD (2x injections, 4 weeks apart)",
      "results": ">90% reduction free C3 in aqueous humor by Day 29, no drug-related SAEs"
    },
    "phase_2": {
      "trial_name": "VERDANT (1497-0002)",
      "nct_id": "NCT06722157",
      "indication": "Geographic Atrophy",
      "status": "Active, not recruiting",
      "design": "Randomized, double-masked, active-controlled, 3-arm (BI 771716 q4w, q8w vs pegcetacoplan q4w), ~180 participants, ~50 US sites",
      "primary_endpoint": "Change in square-root transformed GA area (FAF) slope over 52 weeks",
      "comparator": "Pegcetacoplan (Syfovre)"
    }
  },
  "regulatory_details": {
    "US_IND": "162094 (filed Jul/Aug 2023, approved Aug 2023)"
  },
  "ds_suppliers": [
    {
      "name": "RCV",
      "site": "Biberach/Vienna network",
      "role": "Primary",
      "status": "active"
    }
  ],
  "operational_risks": {
    "medium": [
      "Competitive landscape with pegcetacoplan (Syfovre) and avacincaptad pegol already approved for GA",
      "Need to demonstrate superiority in GA progression with better ocular safety and lower treatment burden"
    ]
  },
  "is_nme": true
},
{
  "product_code": "BI 4041979",
  "product_name": "T3P-Y058-739 (Not disclosed)",
  "modality_name": "Gene Therapy",
  "product_type": "NME",
  "therapeutic_area": "Oncology / Immuno-Oncology",
  "mechanism_of_action": "Dual innate immunity activator (cGAS/RIG-I) via genetically modified Yersinia enterocolitica - bacterial vector immunotherapy that selectively colonizes tumors and delivers immune modulators via Type III secretion system. Activates both cGAS → cGAMP → STING pathway and RIG-I → MAVS/IRF3 signaling, inducing strong Type I Interferon signature to 'heat up' tumor microenvironment.",
  "short_description": "Bacterial vector immunotherapy (attenuated Y. enterocolitica) activating innate immunity via dual cGAS/RIG-I pathways. Phase I evaluating intratumoral and intravenous routes as monotherapy and in combination with PD-1 inhibitors in HNSCC and melanoma.",
  "description": "BI 4041979 (formerly T3P-Y058-739) is a genetically modified, attenuated Yersinia enterocolitica-based bacterial immunotherapy that selectively colonizes solid tumors. The bacteria deliver immune modulators targeting both cGAS (cyclic GMP-AMP synthase) and RIG-I (Retinoic Acid-Inducible Gene I) pathways, resulting in dual activation of innate immunity. This leads to strong Type I Interferon induction via STING (cGAS downstream) and MAVS/IRF3 (RIG-I downstream) signaling. Acquired from T3 Pharma in November 2023. First-in-Human Phase I study (NCT05120596) initiated April 2022 evaluating both intratumoral and intravenous administration as monotherapy and in combination with pembrolizumab in advanced solid tumors. HPSC-defined PoP biomarkers include CXCL10 increase and tumor colonization.",
  "dosage_form": "Live bacterial suspension (attenuated Yersinia enterocolitica)",
  "route_of_administration": "Intratumoral (IT) and Intravenous (IV)",
  "base_technology": "Bacterial vector immunotherapy using Type III secretion system for tumor-selective delivery",
  "current_phase": "Phase I",
  "project_status": "On Track",
  "lead_indication": "Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma",
  "expected_launch_year": 2032,
  "patient_population": "Patients with advanced solid tumors (HNSCC, melanoma) in monotherapy or combination with PD-1 inhibitors",
  "clinical_trials": {
    "phase_1": {
      "trial_name": "T3P-Y058-739 FIH",
      "nct_id": "NCT05120596",
      "indication": "Advanced solid tumors",
      "status": "Active (Started April 2022)",
      "design": "Phase I/II, IT vs IV, Monotherapy ± Pembrolizumab",
      "pop_criteria": "CXCL10 increase, tumor colonization",
      "poc_criteria": "itRECIST local control or ORR"
    }
  },
  "regulatory_details": {
    "Development": [
      "PoP/PoC criteria approved by HPSC (April 2024)",
      "Standalone development post-acquisition until PoC"
    ]
  },
  "operational_risks": {
    "high": [
      "Novel bacterial vector modality with limited clinical precedent",
      "Manufacturing complexity for live attenuated bacteria",
      "Safety profile for tumor-colonizing bacteria (systemic vs local)",
      "Combination therapy optimization with PD-1 inhibitors"
    ],
    "medium": [
      "Competitive landscape with STING agonists showing limited ORR and cytokine toxicities",
      "Need to demonstrate differentiation via dual cGAS/RIG-I activation vs single-pathway agonists"
    ]
  },
  "competitive_positioning": "Differentiates from systemic STING agonists (e.g., TAK-676/dazostinag) through dual cGAS/RIG-I activation, tumor-selective colonization, and both local (IT) and systemic (IV) delivery options. Potentially reduced systemic cytokine burden compared to systemic STING agonists while achieving broader IFN signature.",
  "is_nme": true
}
]